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Although environmental and occupational lead exposure has decreased over the recent 
decades, the health outcomes associated with past lead exposure continue to be a significant 
clinical and public health issue.  Lead is a multitargeted toxicant, that effect skeletal, 
cardiovascular and nervous system.  Mounting evidence supports a link between lead at levels 
previously considered safe, to morbidity and mortality. 
The objective of this dissertation was to examine association of lead biomarkers with 
changes in bone mineral density (BMD), incident fractures and falls, cognition and mortality.  
We utilized data from two epidemiological studies: a) The Study of Osteoporotic Fractures 
(SOF)  that enrolled a population of elderly women (age 65-87), and b)The Lead Occupational 
study that followed a cohort of male lead exposed and control workers through middle age (40-
76 years,63% exposed, 37% controls). 
In the longitudinal SOF analysis, baseline total hip BMD was lower in women with high 
blood lead levels.  The annualized rate of decline in hip BMD was greater among women with 
the high blood lead level, who also experienced a two-fold increased risk of fracture and falls. 
In the longitudinal SOF mortality analysis, women with higher blood lead levels at 
baseline had increased risk of all cause, and cardiovascular mortality compared to women with 
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lower blood lead levels.  No association with cancer mortality was found.  These relationships 
were independent of age and shared risk factors between blood lead levels and BMD, fractures, 
falls and mortality.  
In the Lead Occupational study, compared to controls, lead exposed workers had lower 
total cognitive scores cross sectionally.  In longitudinal analysis, cognitive scores of lead 
exposed workers declined more in compared to controls.  Age and important risk factors of lead 
exposure and cognitive change did not explain this association. 
Overall, our findings provide epidemiological evidence of an association between lead 
exposure, morbidity, and mortality in community residing elderly women as well as a male 
occupational cohort.  A more stringent control of lead exposure and better understanding of the 
mechanism of its effects may help reduce the public health burden of disease.  
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1.0  DISSERTATION OVERVIEW AND OBJECTIVE 
Lead exposure continues to be a public health concern.  Lead is a multitargeted toxicant, 
effecting skeletal, cardiovascular, and nervous system.  Mounting biological and 
epidemiological evidence supports a link between lead at previously considered safe 
levels to morbidity and mortality, in cross sectional as well as longitudinal studies.   
The objective of this dissertation was to examine the association of lead biomarkers 
with changes in bone mineral density (BMD), incident fractures and falls, cognition and 
mortality.  Specifically, the following research questions were addressed in a series of 
three research manuscripts: 
1) Are blood lead levels associated with decline in BMD, incident falls, and fractures? 
2) Are blood lead levels associated with all cause and cause specific mortality? 
3) Is long term occupational lead exposures associated with progressive decrement in 
cognition, and if specific cognitive functions decline more with aging in lead exposed 
workers? 
These research questions were investigated in two epidemiological studies: the Study 
of Osteoporotic Fractures (SOF) that enrolled a population of elderly women, and the Lead 
Occupational study that followed a cohort of male lead exposed and control workers 
through middle age. 
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2.0  INTRODUCTION 
Lead is a metal and has been a pollutant for centuries[1]. Levels of lead in human skeleton 
have increased 1000 fold compared to pre-industrial time[2]. The first major increase in 
environmental lead levels occurred during the industrial revolution and the second  
increase occurred after leaded gasoline [1923] was introduced to improve automobile 
performance[3].  
Over the last two decades, atmospheric lead has decreased around the globe as 
more nations have removed lead from gasoline[4, 5].  About 80% of gasoline sold 
worldwide is lead-free[4]. Other important lead sources are house paint, solders, ceramics, 
and water pipes[6-10]. In the United States(U.S.) although the use of lead in paint peaked 
in 1940 and was banned in 1978, 40% of the housing still contain leaded paint[8, 9]. 
Because of multiplicity of uses, lead persists in air, soil and water and enters the 
body mainly by ingestion or inhalation. The Centers for Disease Control and Prevention 
(CDC) lowered the “acceptable” level of lead in children’s blood to <10 µg/dl in 1991[11]. 
For workers, Occupational Safety and Health Administration(OSHA) mandates that blood 
lead levels be maintained below 50 µg/dl[12, 13].  
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2.1 BACKGROUND 
Global burden of disease due to lead results in about 234 000 (0.4%) deaths and 12.9 
million (0.9%) Disability Adjusted Life Years lost (DALYs)/year [14].  Worldwide, 120 
million people are estimated to have lead levels of 5-10 g/dl, with similar numbers above 
10 g/dl. 40% of children have blood lead levels above 5 g/dl[14]. Following control 
measures, lead levels have been steadily declining in industrialized countries[5, 15]. In 
some developing countries, where leaded gasoline is still used, rapidly increasing traffic 
loads have the potential to increase lead exposures[16-20]. Industrial exposure to lead, 
such as from smelters or battery recycling, presents occupational health burden[15, 21, 
22].  
The National Health and Nutrition Examination Survey (NHANES) II and the first 
phase of NHANES III documented  decline in blood lead levels between 1976-1980 and 
1988-1991[23-25]. Among individuals aged 20 to 74 years, the geometric mean blood lead 
level decreased  from 13.1 to 3.0 µg/dl [26].  A further decline of 41% was noted in the 
second phase of NHANES III conducted in 1988-1994  and the National Health and 
Nutrition Examination Survey conducted in 1999-2002[27, 28].  Overall,  in US adults, 
geometric mean blood lead level  have decreased from 13.1 µg/dl in 1976-1980 to 1.6 
µg/dl in 1999-2002 [26, 27]. Currently, 99% of US adults have blood lead levels below 10 
µg/dl[27].   
Blood lead levels are higher for older children, older adults,  males, African 
Americans, and for central-city residents[26, 29]. Other correlates of higher blood lead 
level include low income, low educational attainment, and residence in the Northeast 
region of the United States[25, 26, 29]. A  trend of rising mean BLL with age is reported, 
with an overall mean blood lead level of 2.7 µg/dl, but 3.7 µg/dl in aged 70 and older[30]. 
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2.1.1 
2.1.2 
Lead exposure and health effects 
Lead is extremely toxic and causes metabolic, neurological and developmental damage to 
the body[31-36]. At high levels, it can cause convulsions, coma, or death[37]. Lower levels 
effects the cardiovascular, neuro-muscular and skeletal system[31-36]. Lead accumulates 
in the liver, kidneys and bones[38]. In women, lead has been linked to increased 
frequency of miscarriages, premature, low birth-weight pregnancy outcome and premature 
menopause[31-36] [39].  
Lead Metabolism and Kinetics  
 
Figure 2-1 Three compartment model of lead metabolism -Journal of Clinical Investigations 
1976;58:260-70(49) 
After lead enters the body, it can travel along several pathways depending on subject’s 
age, sex, nutritional status and genetic background[38]. There are three main 
compartments where lead distributes: blood, soft tissue, and bone (Fig 1). After being 
absorbed from the lungs or gastrointestinal tract, lead first enters the red blood cells 
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(RBCs), where it displaces zinc from the active site of various hematopoietic enzymes[40]. 
Blood lead represents only 1–5% of the total body burden, where it  has a mean  half-life of 
about 40 days in adult males[41]. At lower lead concentrations, 95–99% of blood lead is 
bound to RBCs and only 1% is in plasma. At higher concentrations, the RBCs become 
saturated and more lead is found in plasma.  
Plasma lead can be easily absorbed into soft tissues, primarily the kidney and 
brain, where it exerts its most toxic effects[42].  Plasma lead can readily enter into bone, 
where it replaces calcium in hydroxyapatite crystals.  The concentration of lead in blood 
reflects the equilibrium between current exposure, excretory loss and the movement of 
lead from bone and other deep compartments to blood[42].  Brito et al. (2005) examined 
exchange rates among compartments.  The transfer of lead from blood to other 
compartments was much more rapid than the 1-month estimate reported previously, an 
overall half-life of 10-12 days.  The blood level varies with current exposure and the 
magnitude of the total body burden.  Mean endogenous contribution to  blood lead is 
estimated as 10-20%, in currently employed lead workers, whereas in retired workers, all 
blood lead reflects past exposure[43]. 
2.1.3 Lead: Health Effects in Women 
Lead from blood is incorporated into calcified tissues such as bone and teeth, where it can 
remain for 10 to 30 years[44]. Bone lead comprises 90-95% of the total body burden of 
lead in adults[45]. Lead is slowly released, depending on bone turnover rates, which in 
turn are a function of the type of bone, whether compact (slow turnover) or trabecular 
(rapid turnover)[46].  
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Bone remodeling in states of rapid turnover, such as, pregnancy, lactation, 
menopause and aging allow stored lead to recirculate: described as “endogenous 
contamination”[47].  Popovic et al. (2005) recently reported very different long-term lead 
kinetics between men and women, with premenopausal women appearing to retain lead 
more avidly or release lead more slowly compared to postmenopausal women and 
men[48-50]. 
Lead levels in bone accumulate progressively with age until middle or later life, 
when some decline occurs[51, 52]. The increase in blood lead levels, among recently 
menopausal women suggests that lead may be mobilized at rates consistent with the 
increase in bone loss[45, 52-54]. It has been estimated that trabecular bone loss is 
approximately 2-6 percent per year during the first 3 to 4 years after menopause.  After 
that it decreases for 5-8 years and finally levels off at less than 1 percent per year.  
Cortical bone loss follows a similar but less rapid pattern[45, 52]. 
Increase in blood lead level is highest during early menopause, as bone turnover 
increases dramatically during the first three years, but then slows to a rate only slightly 
above the premenopausal bone loss rate in both Caucasian and African-American 
women[47]. As noted in  NHANES II blood  lead levels were 14.19 µg/dl in nulliparous 
postmenopausal women and 12.97 µg/dl in parous postmenopausal women as compared 
to 11.66µg/dl in premenopausal women[51, 52]. In NHANES II, age, black race, 
postmenopausal status, number of cigarettes smoked and alcohol use had positive 
association with blood lead [51].  
Income and years since menopause were negatively associated with blood lead.  
In addition, number of pregnancies had little impact on blood lead levels  among 
premenopausal women but among postmenopausal women, never-pregnant women had 
higher blood lead levels  than ever-pregnant women[52, 55]. A three-way interaction was 
also observed where the difference between pre and postmenopausal women was 
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greatest in never-pregnant women who were current smokers.  Postmenopausal Mexican-
American women also had higher blood lead levels in the Hispanic Health and Nutritional 
Examination Survey (HHANES 1982-1984)[54].  
2.2 OSTEOPOROSIS 
Osteoporosis is the most common bone disease affecting humans, characterized by 
reduced bone mass with architectural deterioration of the skeleton, and increased risk of 
fracture[56].  
In the US, approximately 20% of white women aged 50 or older have osteoporosis, 
which is defined as  bone mineral density (BMD) greater than 2.5 standard deviations 
below the mean of young, healthy White women[57]. Another 35-50% have low bone 
mass, defined as BMD between 1 and 2.5 standard deviations below the mean[58]. 
Osteoporosis rates vary with ethnicity, with the highest rates in whites and those of Asian 
descent and the lowest rates in blacks[59]. Age increases the rates, which rise from 4% in 
women 50 to 59 years old to 52% for women 80 and older[57]. 
Osteoporosis can occur in both sexes at all ages, but often follows menopause in 
women[60, 61].  Although the process of bone loss begins during a woman’s 30s and 
declines to 70% of its maximum value by the age of 80, osteoporosis occur in 
postmenopausal women, and the incidence increases with age[57]. Several lifestyle 
factors affect the risk of developing osteoporosis: nutrition, physical activity, cigarette 
smoking, and heavy alcohol consumption. Both calcium and vitamin D have a role in bone 
metabolism[62]. 
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2.2.1 Osteoporotic Fractures 
In the U.S., it has been estimated that for white women older than age 50, the risk of 
developing an osteoporotic fracture is nearly 40% in their remaining lifetime, with two-
thirds of the fractures occurring after age 75[56]. Up to 90% of all hip and spine fractures 
in white women aged 65 to 84 years can be attributed to osteoporosis[63, 64]. The 
estimated lifetime risks of hip, vertebral, and forearm fracture for a 50-year-old white 
woman are 17.5%, 15.6%, and 16.0%, respectively[65].  
Black women have about one-third the fracture rate of white women, a difference 
usually attributed to their higher bone mass[66]. Fractures have a devastating toll, 
resulting in higher cost and greater disability and mortality[56, 67]. Hip fractures cause up 
to a 20% increase in mortality within a year of the incident[67]. The pain and deformity can 
greatly restrict normal movement; including Activities of Daily Living (ADL).It takes a 
psychological toll as well: depression is common in women with osteoporosis[68, 69].  
Bone remodeling is the process of bone resorption and bone formation.  
Osteoporosis ensues  when there is an imbalance between bone removal and bone 
replacement.[70].  The osteoblasts promote bone formation by creating a protein matrix 
consisting of collagen, which is calcified, resulting in mineralized bone.  Osteoclasts 
promote bone resorption by production of enzymes that dissolve bone mineral and 
proteins.[70].  
Bone mass increases rapidly throughout childhood.  After a slowing of bone 
mineral accumulation in the late teens, bone mass continues to increase during the 20s, 
and reaches a peak level and then starts declining.  With menopause, bone loss begins to 
accelerate with the decline in circulating levels of 17[beta]-estradiol.  
Bone loss at the spine begins about 1.5 years before the last menstrual period and 
totals approximately 10.5% over 8 years.  Bone mass at the hip has a decline of about 
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0.5% per year before and after menopause, and it sustains an additional estrogen-related 
loss of approximately 5-7% across the menopause transition.  Bone mass continues to 
decline after age 70 and approximately one-third BMD is lost between menopause and 
age 80.  
The major factors influencing bone mass are age, genetics, lifestyle (including 
nutrition), and menopausal status.  80% of the variability in BMD is attributable to genetic 
factors[71].  Female children of women who have osteoporotic fractures have less bone 
mass than expected for their age[71]. Black women have higher BMD than white 
women[72]. Perimenopausal calcium requirements increase in women.  By age 65, 
intestinal calcium absorption declines to less than 50% of that in adolescents and the renal 
enzymes for vitamin D metabolites (which control calcium absorption) decrease.  Regular 
exercise is associated with increases BMD and reduced fracture risk.  Prolonged bed rest, 
or inactivity, is associated with rapid bone loss[73].   
Compared with nonsmokers, women smokers tend to lose bone more rapidly, have 
lower bone mass, and reach menopause up to 2 years earlier.  Postmenopausal women 
smokers have  higher fracture rates than nonsmokers[74]. Cigarette smoke interferes with 
calcium absorption and lowers endogenous 17[beta]-estradiol levels[75, 76]. Excessive 
alcohol consumption has detrimental effects on BMD and increases the risk for falls and 
hip fracture.  Moderate alcohol consumption in women ≥ 65 years increases BMD [75].  
BMD is a strong predictor of fracture risk because bone mass accounts for 75-85% 
of the variation in bone strength.  BMD testing is the preferred method to diagnose 
osteoporosis and is recommended in all women 65 years of age.  Dual-energy x-ray 
absorptiometry (DXA) is the technical standard for measuring BMD[77]. Results are 
reported as standard deviations, Z score or a T score.  A Z score is based on the standard 
deviation (SD) from the mean BMD of a reference population of the same sex, ethnicity, 
and age[78]. A T score is based on the mean peak BMD of a normal, young adult 
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population and is expressed in terms of standard deviations from the average value of this 
reference population.  
Every decrease of one standard deviation from age-adjusted bone density 
represents approximately a 10-12% change in BMD and an increase in the risk of fracture 
by a factor of approximately 1.5.  In general, postmenopausal women lose about 0.5 in 
standard deviations from the mean in both T and Z scores every 5 years.  In 1994, the 
World Health Organization (WHO) defined osteoporosis as a BMD T score below -2.5 SD 
based on measurements of any skeletal site[60].  
2.3 
2.3.1 
LEAD AND BONE 
Biological Evidence  
Skeleton sequesters 95% of stored lead in different bone cells such as osteoclasts, 
osteoblasts, osteocytes, and growth plate chondrocyte[46]. However, most studies on the 
toxic effect of lead fail to address its effects on the skeleton itself[79].  The skeleton is 
maintained through a balance between osteoclastic resorption and osteoblastic bone 
formation[61]. Low serum level of calcium stimulates parathyroid hormone release which 
acts on osteoblasts to secrete a factor that activates osteoclasts[46]. Osteoclastic bone 
resorption restores the calcium levels; however, to maintain an appropriate skeletal mass, 
the lacunae created by the osteoclasts must ultimately be refilled with bone. Bone 
formation within the lacunae is mediated by osteoblastic activity[80]. 
Lead exposure can interfere with bone and calcium metabolism in several ways[46, 
81]. Lead and calcium have similar physical and chemical characteristics and follow similar 
metabolic pathways[82]. In the skeleton, lead is contained in the mineral matrix, in close 
  10
chemical association with calcium and phosphate[44]. Lead can compete with calcium in 
intestinal absorption and deposition into bone, regulated by regulated by parathyroid 
hormone (PTH), 1, 25-dihydroxyvitamin D, and other factors[46]. Increases in serum PTH 
and 1, 25-dihydroxyvitamin D have been reported  in occupational lead exposure[49, 79]. 
Bone resorption by PTH over a long period may lead to serious bone decalcification and 
may increase the risk for osteoporosis[83].  
Studies indicate that lead exerts both direct (osteoblast and osteoclast function) 
and indirect (kidney dysfunction) actions on bone turnover[80]. Since skeletal mass is 
decreased in lead intoxicated animals and humans, bone formation must be decreased 
relative to the level of bone resorption. Studies on isolated normal cells and in vivo 
experiments show that lead inhibits secretion of osteonectin in ROS 17/2.8 cells and 
affects osteoblast cell proliferation[81, 84].  Lead intoxicated bone, is resistant to 
osteoclastic bone resorption[85]. 
There is evidence that lead can cause osteoporosis in animal models[86]. Animal 
studies have shown an association between increased bone lead concentration and lower 
bone mass and decreased mechanical strength[87, 88]. Lead induced inhibition of axial 
bone development and a decrease in bone mass, produced by enhanced resorption, and 
increase in bone mass, produced by lead accumulation in bone[89]. Osteopenia is induced 
by long-term, low level and high-level exposure of the adult rat to lead[90]. Findings show 
that lead is incorporated into bone mineral after only 1 month of exposure to low lead 
(0.01%, 100 ppm), with significant osteopenia after 12 months of exposure; high lead 
(0.5%, 5000 ppm) caused osteopenia at 1 months. No compensatory mechanism was 
elicited to maintain bone mass[90]. 
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2.3.2 Epidemiological Evidence 
In growing children, lead exposure can stunt bone growth by affecting endochondral bone 
formation[79, 91-93].  In the NHANES II blood lead level  was inversely related to  growth 
in height, weight, and chest circumference in children[94]. In a follow-up study of children 
who had elevated postnatal blood lead levels, lower height was attained at 18 months of 
age[95].  
Endogenous lead release occurs during activation of the skeleton in 
menopause[52]. Cortical bone, which contains the greatest amounts of lead, its 
remodeling at the menopause could compromise mechanical support, predisposing to 
fractures.  The effect of lead on growing bone and adult remodeling could predispose to 
osteoporotic fractures.  A hypothetical “Lead-exposed female” never reaches the peak 
bone density of her unexposed female counterpart because of compromised growth plate 
chondrocyte activity.  At menopause, activated bone turnover and an exposure to released 
lead would accelerate the decline in bone density such that the “Lead-exposed female” 
would cross over a fracture threshold earlier.  
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 Figure 2-2 Model of Lead exposure and BMD change  and fracture threshold .Source Nutrition and 
Bone Health 2004 
2.4 LEAD AND FALLS 
One third of people aged 65 and older fall each year, and this proportion increases to one 
half by 80 years of age. Falls account for 87% of the fractures, and fall related injuries for 
5.3% of all hospitalizations at age 65 and older[96]. Psychological impact of falls result in 
disability, fear of future falls, restriction of activities and mobility, and nursing home 
admissions[68, 97].  
Contributing factors for risk of falls include female sex, selected chronic diseases, 
medications and disabilities[98-100]. Epidemiological studies in community dwelling 
elderly have shown higher prevalence rates of 22% in women, to 7% in men. Functional 
status indicators are also associated with falling. Slower walking speed is a risk factor for 
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recurrent falls and also a predictor of hip fracture[101]. Impairment of leg extensor muscle 
strength, grip strength, balance and gait are risk factors for  falls[101].  
Loss of pressure sensitivity (peripheral neuropathy) is associated with reduced 
balance. Impaired vision and hearing may increase the risk of falls in older individuals[96, 
102]. Hearing sensitivity may be adversely affected by osteoporotic bone loss. Those with 
hearing loss may be more likely to have impaired balance and thus be more prone to falls 
and fractures. Hearing sensitivity has been associated with decreased vestibular 
function[103-108]. Poor balance and postural instability is increased in individuals with 
lead who also have peripheral neuropathy.[109] 
Lead exposure could predispose to fractures because of increased risk of falls as it 
effects neuromuscular function  and balance[110, 111].  Lead exposure in childhood has 
been associated with impaired  maturation of postural balance and central auditory 
processing[112-114]. Lead slows the nerve conduction velocities in peripheral nerves 
which effects motor coordination, perception of vibration, light touch and position of the 
joints[113, 115, 116]. 
Muscle is one of the soft tissues where lead is deposited in addition to skeletal, 
nervous and renal tissues.  Muscle weakness and easy fatigue occur early and may be the 
only symptoms of lead exposure[114]. The muscle groups usually involved are the most 
active ones, such as the extensors of the forearms, wrist and fingers[117]. Blood lead 
levels as low as 8 µg/dl were associated with poorer performance on tests of visual 
perception, manual dexterity and psychomotor speed[118].  
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2.5 
2.5.1 
LEAD AND MORBIDITY 
Lead is a multitargeted toxicant, effecting cardiovascular, renal, and nervous systems and 
may contribute to a fraction of associated morbidity and mortality.  
Cardiovascular morbidity 
Biological evidence  
Lead-fed animals have increased vascular reactivity to norepinephrine[119]. Picomolar 
concentrations of lead have been shown to activate protein kinase C, a major regulator of 
vascular tone. Increases in blood pressure and renal damage have been observed after 
induction of lead exposure in rodent models[120].[121] . 
Epidemiological evidence  
In adults, the cardiovascular (CVD)system is very sensitive to lead exposure[131]. 
Research  indicates that blood lead levels <10 µg/dl are associated with peripheral arterial 
disease, impaired renal function, and elevated blood pressure[132, 133].  Hypertension 
associated with lead exposure has been documented in occupational cohorts as well as in 
general population[132].[134-141] In one study, blood lead levels were non-significantly 
higher in incident cases of ischemic heart disease and stroke than in non cases, although 
the number of events was smaller (n=316 and 66 cases of ischemic heart disease and 
stroke, respectively) than in the NHANES studies[140]. The average blood lead levels in 
the study were also relatively high (mean 15.3 µg/dl). In a meta-analysis of 15 studies,  a 
5-µg/dl increase in blood lead  was associated with an increase in systolic blood pressure 
of 1.25 mm Hg[142]. An association of elevated blood pressure due to lead with risks for 
more serious cardiovascular events has not been evaluated. 
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2.5.2 Lead and Carcinogenesis: Biological evidence 
Based on biological  evidence, mechanisms of lead carcinogenesis include mutagenicity,  
tumor promotion and cellular proliferation[122]. Lead is a weak mutagen and can disturb 
DNA synthesis or repair[123, 124]. Lead may exert diverse toxic effects on cells, disrupting 
the ability of cells to develop appropriate response to genotoxic agents. Lead enhances 
the mutagenicity of radiation and other carcinogens[123, 124].  
The National Toxicology Program classifies lead as “reasonably anticipated to be 
human carcinogens. “The International Agency for Research on Cancer (IARC) rates lead 
as possibly carcinogenic to humans (2004)(Group 2B)[125-128]. The Environmental 
Protection Agency uses a similar classification scheme to that of IARC for lead.  
Epidemiological evidence 
Most of the evidence on the relationship between lead exposure and cancer comes from 
review of  8 studies of lead exposed workers by Steenland and Boffetta in 2000[123, 124, 
129, 130].The relative risk of developing cancers of brain, stomach, lung, colon and kidney 
were higher with higher lead exposure.  Increased risk of cancer mortality was observed in 
individuals with >20 µg/dl blood lead levels in NHANESII[123], this risk was not observed 
at levels <10 µg/dl[123]. 
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2.6 
2.6.1 
LEAD AND MORTALITY  
Epidemiological evidence 
Several occupational studies report the association of lead exposure and mortality.  
Gerhardsson et.  al  reported increased all-cause mortality in lead-exposed workers[143, 
144]. McDonald and Potter reported increased all-cause, cardiovascular and 
cerebrovascular deaths in a study of 454 children longitudinally ( hospitalized for lead 
poisoning between 1923 and 1966)[145].  Moller and Kristensen documented association 
of  blood lead with all-cause mortality in a population-based survey in Copenhagen, 
Denmark[146].  
Lustberg et al analyzed data from NHANES  (1976-1980) and reported that 
individuals with blood lead level 20 to 29 µg/dl experienced 46 % increased all cause, 39% 
circulatory disease, and 68% mortality due to cancer relative to those with < 10 µg/dl.  
Analysis of cause specific cancer mortality indicated that blood lead was associated with 
mortality due to lung, stomach and kidney cancer(N=9250[123, 147].  
Schober et al. analyzed mortality data for individual’s ≥ 40 years of age in the 
NHANES III (1988-1994)[147].  Blood lead levels 5-9 µg/dL were associated with 24 % 
increased risk of death from all causes, 20% increased cardiovascular , and 44% 
increased cancer mortality(N=9757).  Menke et al documented 25% increased all cause 
and 55% increased cardiovascular mortality in NHANES III (1988-1994) data at  blood 
lead levels of >3.62 µg/dl as compared to those with <1.94 µg/dl[148].  However they did 
not observe an association between blood lead and cancer mortality in this range of 
exposure.  This increased mortality effected non-Hispanic whites, non-Hispanic blacks, 
and Mexican Americans and both males and females (N=13,946) 
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2.7 
2.7.1 
2.7.2 
LEAD AND CONGITIVE EFFECTS 
Adults with occupational exposures have neurologic deficits at blood lead levels of 50 µ 
g/dl[149-151]. The older brain may be especially vulnerable to the effects of lead[30, 152]. 
Recent studies have begun to examine the relation between relatively low levels of lead 
exposure and cognitive function in community-dwelling older adults[153].  
Peripheral nervous system  
Epidemiological and biological research has associated lead with peripheral neuropathy, 
axonal degeneration and impaired nerve conduction velocity[154-156]. In the human 
peripheral nervous system, the motor axons are the principal target of lead[157-160]. 
Perception of vibration, light touch and position of the joints is effected when lead 
damages these fibers. Lead exposure may cause muscle weakness and easy fatigability. 
The most active fibers affected are the extensors of the forearms, wrist and fingers and the 
extractor muscles. Lead may be taken up from muscle by motor axons and transported 
back to nerve cell bodies in the spinal cord, where it may damage vital cellular processes. 
At lower levels of lead exposure, motor nerve conduction velocity, and coordination is 
decreased. 
Central nervous system 
Diminished neuropsychological performance has been observed in lead exposed 
workers[156]. Visual intelligence and visual motor coordination is affected[153, 161]. Lead 
disrupts the blood brain barrier and increases permeability to the free lead ion[162]. Lead 
accumulates in distinct anatomical regions: Hippocamus, frontal cortex or disturbs 
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neurotransmitters in brain. Lead effects upon the CNS may be mediated by disturbing  
mitochondrial energy metabolism, which then influences other metabolic processes[162, 
163]. Lead disrupts oxidative phosphorylation in mitochondria  also disrupts cytochrome 
metabolism[164-169]. 
Epidemiological studies report an inverse association between different measures 
of cumulative lead exposure and  tests of cognitive function in both occupational cohorts 
and general population[35, 170-173].  One of the general population studies found that 
blood lead levels as low as 8 µg/dl were significantly associated with impairment on 
several neuropsychological tests among a cohort of rural women but not urban 
women[118]. 
Occupational studies have reported the relationship of cumulative exposure as 
measured by bone lead with cognitive decrement[153].  Acute exposures to high levels of 
lead among adults has been associated with deficits in performance on visuospatial skills, 
motor function, reaction time,  memory, spatial,  attention  and concentration[174-177]. 
Fewer studies have examined the association between cumulative lead exposure over 
longer time  and cognitive function in these populations partly because of difficulty in 
obtaining good biomarkers for cumulative exposure[150]. 
More recent studies have examined this issue using K-XRF technology to measure 
lead in bone such as tibia and patella[178-180]. In general, the cognitive effects 
persistently associated with higher  bone lead levels are executive function/attention and 
visuospatial /visuomotor tasks, although associations with verbal and memory tasks are 
also noted[174, 180]. The studies that analyzed cognitive performance over time, 
document inverse association between tibia  lead levels and, decreased performance on 
executive function/attention and manual dexterity[181, 182].  
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The mechanism underlying the effects of lead on nervous system have been of 
more recent interest. Lead accumulates in astroglia, which are essential for maintenance 
of neuronal environment[183].  Lead exposure can interfere with several calcium 
dependent processes[162].   
Magnetic Resonance Imaging (MRI) studies have documented  the association of 
higher tibia lead  with increased prevalence and severity of white matter lesions and 
smaller structure-specific brain volume [184]. Cerebral white matter changes on MRI are 
associated with higher bone lead levels and psychomotor slowing as measured by 
Grooved Pegboard test [178, 184, 185]. Tibia lead has been  associated with the strongest 
effects on verbal memory and learning, visual memory, and executive function which  may 
indicate disruption of widely distributed neural networks involved in the integration of 
functions and would be consistent with lesions to cortical association areas[184].  
Adult exposure to lead could accelerate age-associated changes in white 
matter[186]. Myelination continues into the fifth and possibly sixth decade of life  in 
selective brain regions (e.g., inferior temporal, prefrontal, and temporoparietal 
regions)[187]. White matter produced later in life around cells with long but small caliber 
projections in cortico-cortical association areas may be sensitive to oxidative stress[188]. 
The significant associations of tibia lead  with the parietal white and gray matter, temporal 
white matter, suggest that lead accelerates an age-associated process in selected brain 
regions[188, 189]. No significant associations were observed in regions  where 
myelination occurs early in life (e.g., occipital lobe and cerebellum) and where short axonal 
projections are relatively common[189]. 
High blood pressure is  also correlated with number of white matter lesions and 
total brain volume[184, 190]. Lead exposure is a risk factor for hypertension, which may 
cause cerebrovascular disease leading to poor performance on cognitive tests[191-193]. 
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Decreased ratio of N-acetylaspartate (NAA) to creatine, a marker of neuronal density in 
hippocampus and frontal lobe as measured by Magnetic Resonance Spectroscopy (MRS) 
neuroimaging studies,  is associated with higher bone lead levels and  deficit on attention / 
executive function, visuospatial /visuomotor functioning and short term memory[194]. Lead 
induces neurofibrillary tangles in  frontal cortex and hippocampus, and is selectively toxic 
to limbic system, that modulates behavior, emotions, learning and memory[195-197]. 
Lead and homocysteine are both associated with cardiovascular disease and 
cognitive dysfunction[186].  An association between blood lead and homocysteine has 
been documented which  suggest that homocysteine could be a mechanism that underlies 
the effects of lead on the cardiovascular and central nervous systems, possibly offering 
new targets for intervention to prevent the long-term consequences of lead exposure[186, 
198]. More advanced imaging techniques such as FLAIR, structural, functional, CT, MRI, 
SPECT,PET, MRS will likely advance understanding of how lead affects brain. 
2.8 LEAD BIOMONITORING 
The laboratory-based methods include direct determinations of lead in blood and in urine 
and components of the heme biosynthetic pathway, which is inhibited by lead.  
Assessment  of recent exposure is achieved by direct measurement of lead in blood[199]. 
Blood lead levels can be reliable measured at concentrations as low as 1µg/dl using 
atomic absorption spectrophotometry[200-203]. Small hand held instruments for rapid 
direct measurement of blood lead in field are also available.  The cumulative time-
integrated blood lead index reflects both the duration and intensity of lead exposure. 
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Measurements of the heme precursors free erythrocyte protoporphyrin (FEP) and 
erythrocyte zinc protoporphyrin (ZnP) have also been used for screening purposes.  A 
more accurate picture of the overall lead body burden can be provided by the provocative 
chelation test: calcium disodium ethylene-diamine-tetraacetic acid (CaNa2EDTA), lead is 
mobilized from the soft tissues and excreted in the urine, where it is quantified by atomic 
absorption.  Historically, wet chemical digestion of bone followed by atomic absorption-
based measurements was done on cadaver or bone biopsy samples.  Measurement of 
tooth lead is performed on shed primary teeth to assess lead exposure in children.   
X-Ray Fluorescence 
Over the past two decades, the technique of x-ray fluorescence (XRF) has emerged as a 
noninvasive method for bone lead determination, enabling direct in vivo measurements of 
skeletal lead.  XRF occurs when absorption of a high-energy photon by a heavy metal 
atom induces the emission of a second x-ray photon of slightly lower energy.  A typical x-
ray fluorometer designed for in vivo measurements features a radioactive 109Cd source, 
which emits at 88.035 keV, and a germanium crystal detector arranged in backscatter 
geometry (i.e., the detector is mounted behind the source).  During a typical in vivo bone 
lead measurement, the bone is irradiated for 30–60 min, and the generated photons are 
collected and counted.  This yields a measurement of bone lead in units of µg lead/g of 
bone mineral.  The best site for assessment is a large dense bone with little overlying 
tissue; therefore, the tibia is preferred.  
Bone lead as marker for cumulative exposure was established in heavily exposed 
workers.  A time-integrated cumulative blood lead index was calculated from the recorded 
blood lead values and correlated to measurements of bone lead for four studies that 
ranged from 0.67 to 0.88.  A time-weighted average blood lead was calculated to reflect 
the intensity of the exposure, and bone lead was measured in the tibia and calcaneus of 
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91 active lead workers: tibia lead concentration is related to both the duration and the 
intensity of exposure, whereas trabecular calcaneus bone reflects only the intensity.  
Trabecular bone lead is rapidly exchangeable bone lead compartment, in contrast to 
cortical lead.  
2.9 OCCUPATIONAL LEAD EXPOSURE 
Workers in smelters, refineries and other industries may be exposed to high levels of lead.  
Lead dust may be breathed in and can also cling to skin, hair, clothing, and vehicles, and 
be carried to the home, exposing workers’ families.  According to estimates made by the 
National Institute of Occupational Safety and Health (NIOSH), more than 3 million workers 
in the United States are potentially exposed to lead in the workplace.  
Occupational exposure to lead in general industry is regulated by the 1978 
Occupational Safety and Health Administration (OSHA) Lead Standard.  The general 
industry standard specifies permissible limits on airborne lead exposure, as well as BLL.  
For workers in the United States who are covered by the OSHA lead standard, a detailed 
medical examination is delineated under specific conditions. 
Any general industry worker (i.e., battery, foundry, smelting, mining, glass, 
ceramics) found to have a single blood lead level of 60 µg/dl or greater, or an average 
blood lead level of 50 µg/dl or greater must be removed from the high-exposure job 
(termed “medical removal protection”).  The “removed” worker should subsequently 
receive more frequent medical evaluation and blood testing.  A worker is not allowed to 
return to a job with the potential for high lead exposure until his or her blood lead level has 
fallen below 40 µg/dl on two successive tests.  
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As the skeleton is a major storage site for lead accumulation (90–95% of the total 
body burden), in lead workers, this fraction may be even higher.  For example, skeletal 
lead content in lead workers is 1 g compared with 100 mg in non-occupationally exposed 
persons and a few milligrams in prehistoric persons.  If this pool of bone lead is mobilized 
rapidly, it may constitute a health risk by impacting blood lead levels, especially among 
workers exposed long term to lead.  Hence, bone lead is a valuable biomarker in 
epidemiologic studies. 
2.10 LIMITATIONS OF THE EXISTING EPIDEMIOLOGICAL LITERATURE 
Although several lines of evidence support a link between lead biomarkers and multiple 
health outcomes, the underlying mechanisms are not understood.  Reports have generally 
focused on cognitive effects in children and occupational exposure in men.  Less is known 
about the effects of lead exposure in women in occupational as well environmental 
settings and chronic disease outcomes.  Epidemiological studies conducted at population 
level (NHANES) have not used the state of the art XRF-technology to associate the 
cumulative lead levels to health effects.  In the existing literature, blood lead levels have 
been used, which may not measure cumulative exposure at population level. 
  Some of the methodological weaknesses in earlier research were sampling 
inadequacies, selection bias, and variation in data collection procedures, reliance on 
current indices of lead exposure rather than cumulative exposure indices, inaccurate 
measurement of exposure and / or dose, inadequate sensitivity of the neuropsychological 
tests used for detecting central nervous system effects.  
Occupational studies grouped individuals as exposed or non –exposed, but the 
non exposed volunteers were often not screened for prior lead exposure.  The exposed 
  24
and non-exposed were often not comparable with respect to demographic and pre-morbid 
characteristics.  Bias could have been introduced in these occupational studies because of 
non blind examiners.  Many studies did not include important confounders of lead 
exposure, e.g., socio-economic status, age, and education.  Finally, inaccurate estimates 
of lead exposure, or about other confounding variables such as alcohol consumption, 
would bias the study towards finding association.  
Studies of chronic lead exposure rely either on determinations of current blood 
level or historical reconstructions of exposures from past blood levels.  To avoid the 
limitations of cross-sectional studies comparing BLL, a prospective repeated-measures 
design is needed.  Specifically, baseline XRF analysis of lead in bone and BLL at baseline 
and at selected intervals should be performed.  Bone densitometry should ideally be 
performed at the same intervals to determine bone turnover.  
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3.1 ABSTRACT 
BACKGROUND: Lead disturbs neuromuscular functions, affects bone turnover, and 
decreases growth and stature in children.  Lead is stored in the skeleton; post-menopausal 
women have higher Blood Lead Level (BLL) than pre-menopausal women.  Whether lead 
is associated with bone loss and fracture and falls risk in older women is not established.   
METHODS To test the hypothesis that women with higher BLL experience faster rates of 
decline in bone mineral density (BMD), and higher falls and fracture rates, we measured 
BLL in 533 white women aged 65-87 years in 1990-91 by atomic absorption 
spectrophotometry. Total hip BMD was measured twice by dual energy x-ray 
absorptiometry 3.3 years apart.  Information on falls was collected every 4 months for 3 
years.  Incident non-spine fractures were identified over 10 years of >95% complete 
follow-up.  Fractures were confirmed by radiographic report.  We used ANCOVA to 
compare BMD and annualized (%) decline in BMD across three categories of BLL (µg/dl):  
low (≤3), medium (4-7) and high (≥8).  Proportional hazards models were used to calculate 
the Hazard Ratio (HR) and 95% Confidence Intervals (CI) of fracture; the low BLL 
category formed the referent group.  Poisson Regression with Generalized Estimating 
Equations was used to calculate multivariate adjusted fall Incidence Rate Ratios (IRR) and 
95% CI.  We adjusted for age, physical activity, calcium and Vitamin D use, history of 
fractures, maternal history of fractures, cognitive function, and baseline BMD. 
RESULTS:  The mean blood lead level was 5.3 µg/dl ±2.3 and ranged from 1-21 µg/dl.  
Women in the high BLL category were older, had lived more years after menopause, and 
had lower body weight, height, and body mass index (BMI) than women with low BLL.  
Baseline total hip BMD was 7% lower in high BLL category compared to low BLL (p<0.02).  
The annualized rate of decline in hip BMD was 3 times greater among women with the 
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high BLL.  Women with high BLL had a 74% increased risk of fracture (HR = 1.74; 1.01-
2.98) and 87% higher risk of falls (HR = 1.24; 1.24-2.82), compared to women with low 
BLL, independent of BMD and other covariates. 
CONCLUSIONS: High BLL were associated with low baseline BMD, greater rate of 
decline in BMD, and increased risk of falls and fractures.  This association was found at 
blood lead levels previously thought to be safe.  Further reductions in BLL could lead to a 
decrease in falls and osteoporotic fractures. 
3.2 INTRODUCTION 
The skeleton is the major repository for lead within the body, sequestering up to 95 
percent of lead and can be an endogenous source of lead for many years after 
exposure.[1]  Lead may be mobilized from skeletal stores during conditions of high bone 
turnover, such as pregnancy, lactation, menopause and aging[2].  Indeed, blood lead 
levels are higher in postmenopausal women in comparison to premenopausal women[2, 
3].  Lead is contained in the mineral matrix of bone in close association with calcium, 
sharing many physical and chemical characteristics and intracellular pathways.  Lead can 
compete with calcium in intestinal absorption and deposition into bone.  Analogous to 
calcium, lead absorption from the intestine is regulated by parathyroid hormone (PTH), 1, 
25-dihydroxyvitamin D, and other factors.  Studies indicate that lead may exert both direct 
(osteoblast and osteoclast function) and indirect (kidney dysfunction) actions on bone 
turnover[4]. In addition to effects on bone, lead exposure could predispose to fractures 
because of increased risk of falls as it affects neuromuscular function and balance.  Lead 
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exposure in childhood has been associated with impaired  maturation of postural balance 
and central auditory processing[5, 6].  
In the current study, we examined the association between blood lead levels and 
rates of decline in BMD, falls and fractures in a subset of 533 women enrolled in the Study 
of Osteoporotic Fractures (SOF). We hypothesized that women with higher blood lead 
levels will experience faster rates of bone loss and a greater risk of falls and fractures. 
3.3 
3.3.1 
METHODS 
Study Population 
The Study of Osteoporotic Fractures (SOF) is a longitudinal cohort study that enrolled 
9704 white women from 1986 to 1988 using population-based listings in Baltimore, MD; 
Minneapolis, MN; Portland, OR; and the Monongahela Valley near Pittsburgh, PA.  To be 
eligible to participate, women had to be aged 65 years or older and ambulatory. 
The lead ancillary study was conducted in 1990-1991 in 533 white women aged 
65-87 years enrolled in SOF at either the University of Pittsburgh or University of Maryland 
clinics.  Initially, we  examined the correlates of blood lead and the association of blood 
lead level to cognitive function [7]. We found a relationship between  higher blood lead 
levels and worse cognitive function as measured by the part B of Trailmaking Test, but this 
association was confined to the rural SOF clinic [7, 8].  In the current paper, we extend the 
lead study to outcomes of bone mineral density, rates of decline in BMD and incident 
fractures and falls.  The protocol and consent forms were approved by the institutional 
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review boards at the participating institutions.  All women provided written informed 
consent. 
3.3.2 
3.3.3 
Bone Mineral Density 
Bone mineral density (BMD) was defined as the amount in grams of bone mineral content 
divided by the region of interest in centimeters squared.  BMD of total hip and femoral 
neck were measured twice at the second (1988-1990) and fourth examination (1993-1994) 
by DXA using Hologic QDR 1000 scanners (Bedford, Mass) an average of 3.5 years apart.  
Calcaneal BMD was measured at baseline (1986-1988) and at fourth visit (1993-1994),  
with OsteoAnalyzers (Siemens-Osteon, Wahiawa, HI) using single photon absorptiometry 
at the baseline examination and single X-ray absorptiometry (Osteoanalyzer, Dove 
Medical Systems) at the fourth examination (mean follow-up=5.7years).  Annual percent 
decline in BMD was estimated for the femoral neck, total hip, and calcaneus.  Details of 
the measurement and densitometry quality-control procedures have been published [9]. A 
random sample of scans was reviewed by technicians at a quality-control center.  To 
assess longitudinal performance of the scanners, a spine phantom was scanned daily and 
a hip phantom was scanned once per week at each clinic. 
Other Measurements 
Potential confounders of the association between blood lead levels and outcomes of 
interest (BMD, fractures and falls)  were identified and adjusted for. Sociodemographic 
factors (age, study site/clinic, education), smoking history, alcohol consumption (past 30 
days), and physical activity from walking, medication use [including hormone therapy, 
Thiazide diuretics, systemic corticosteroids, calcium supplements, vitamin D supplements, 
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Central Nervous System (CNS) active medications: benzodiazepines, antidepressants, 
anticonvulsants and  narcotics], and time since menopause, number of children breastfed, 
health status compared to others, history of fractures after age 50 and history of maternal 
fractures,  incident falls over the previous one year were determined by an interview–
administered questionnaire. 
Health impairment data included cognitive impairment, assessed as scores on 
Trailmaking Part B, functional status impairment, and depression as 6 or more depressive 
symptoms on the 15-item Geriatric Depression Scale Shortened.  Prevalent chronic 
conditions such as diabetes, hypertension, arthritis, stroke, Parkinsonism, COPD, angina 
were defined as self-report of the condition previously diagnosed by a physician. Height 
and weight were obtained using a Harpenden stadiometer (Holtain Ltd, Crymych, UK) and 
a standard balance beam, respectively, and body mass index (BMI) was calculated as 
weight divided by height squared (Kg/m2).  Systolic and diastolic blood pressure was 
measured by manual mercury sphygmomanometer.  Physical function was assessed 
including grip strength measured as average of right and left using an adjustable hand grip 
dynameter in Kg (Preston Grip Dynameter; Takei Kiki Kogyo, Tokyo, Japan), walking 
speed (second /6 meters), use of arms for 5 chair stands, corrected visual acuity, static 
balance as the ability to hold a standing tandem position for 10 seconds with eyes closed. 
3.3.4 Fracture Ascertainment 
After the initial enrollment visit, all women were contacted by either postcard or telephone 
every 4 months to determine whether any fractures had occurred in the preceding 4-
months.  After more than 10 years, fracture follow-up remains over 95% complete.  
Women who reported a fracture were interviewed by telephone about the circumstances 
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under which the fracture occurred.  Fractures occurring because of a major trauma, e.g., 
motor vehicle crash were excluded.  Women could report having more than 1 fracture.  All 
fractures were confirmed by radiographic report.  The time to first fracture was calculated 
as time from the baseline BMD measure to the event. 
3.3.5 
3.3.6 
Falls  
Data were prospectively collected on the number of falls using a series of postcards 
mailed every 4 months for 3 years following baseline visit.  On each postcard, participants 
were asked if they had fallen in the past 4 months and, if so, how many times.  
Participants were contacted by phone when postcards were not returned.  Follow-up on 
postcard mailings were 95% complete. 
Blood Lead Measurements 
A 5.0 ml sample of whole blood was drawn into Vacutainer tubes (BD Vacutainer Systems, 
Rutherford, New Jersey).  Blood samples were analyzed at the Clinical Chemistry 
Laboratory of the University of Maryland, certified for the analysis of lead in blood by the 
Occupational Safety and Health Administration and Centers for Disease Control and 
Prevention, and documents a lower limit of detection for lead of 1µg/dL.  BLL were 
determined by graphite furnace atomic absorption spectrometry (AAS model 5100, HGA 
with Zeeman Effect background correction: Perkin Elmer, Norwalk, Connecticut).  To 
investigate  intralaboratory variability in both the measurement of blood lead level and the 
stability of blood lead levels over 1year in this population, additional blood samples were 
collected from a random sample of participants in the Study of Osteoporotic Fractures[7]. 
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The sample distribution was selected to represent the two clinic distributions of blood lead 
analyzed at the laboratory.  Two tubes of blood were drawn from each of the 100 randomly 
selected women (50 women from each clinic) for this purpose during a later clinic visit.  
The laboratory was blind with respect to the second blood sample and therefore the 
intralaboratory variability in both the measurement of blood lead level and the stability of 
blood lead levels over time was determined.  The intraclass correlation coefficient for the 
duplicates was 0.88.  Mean values of 4.76 µg/dl (range, 1-13 µg/dl) and 4.67µg/dl (range, 
1-12 µg/dl) were obtained for the first and second determinations, respectively. 
3.4 STATISTICAL ANALYSES 
All analyses were performed by categorizing the study participants into three groups of 
blood lead level (BLL) corresponding to the upper and lower 15th percentiles of the 
distribution of blood lead variable.  Thus the three groups were: low ( ≤3 µg/dl, n=122), 
medium (4-7 µg/dl, n=332), and high( ≥8  µg/dl, n=79)[7]. 
Chi-square test was used to test baseline characteristics for categorical variables 
by BLL status; ANOVA was used for continuous variables.  Two-tailed p-values were used 
for all tests, at 5% statistical significance.  Fracture incidence rate was calculated per 
1,000 woman-years of follow-up for each BLL group.  We used Cox proportional hazard 
regression analysis to estimate the relative risk (RR) of fracture and 95% confidence 
interval (CI).  We plotted the cumulative hazard of fractures in the three BLL groups over 
the follow-up period by Kaplan- Meier Survival graphs.  For each blood lead level 
category, the relative risk (RR) of falls was computed using Poisson regression models 
with generalized estimating equations (GEE) to adjust standard errors for correlated data 
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points at 4-month intervals.  A Huber White Sandwich estimator of variance was used with 
GEE to construct valid standard errors.  The RR was computed as fall rate (average 
number of falls per 4 months) in a specific category of blood lead level compared to the 
lowest or the referent category. 
In multivariate models, we simultaneously analyzed blood lead levels and other 
potential risk factors.  We included variables that were significantly associated with 
respective outcomes (BMD, fractures, and falls) or blood lead levels either reported in the 
literature or from preliminary univariate analysis.  A forward stepwise selection process 
was used to add or remove potential covariates from the multivariate regression models 
(exit criteria: p≥.15).  We organized variables into 9 related groups, including 1) 
demographic factors :age, education, clinic, 2)anthropometric measures : height ,weight, 
BMI, weight change, weight loss since age 50, 3) lifestyle factors: smoking, alcohol intake 
past 30 days, walk for exercise,  4) physical functions:  average grip strength, walk speed, 
use arms to stand up from chair, 5)health status: health compared to others, depression, 
functional limitation,  6)functional  performance: Trailmaking part B, depression,  7) self 
reported medical history: hypertension, diabetes, stroke, angina, 8) medication and 
supplement use: hormone therapy, Vitamin D, calcium and thiazide diuretic, 
9)reproductive factors: years after menopause, ever breastfed. Sequential models were 
analyzed in which all variables in one group were allowed to enter in a stepwise regression 
based on p- value at each step.  The next model began with the significant variables 
remaining from the previous model.  Then a new group of variables was allowed to enter, 
using the stepwise entry procedure, for successive groups of variables, until a final model 
of significant variables was selected.  We computed overall and age-adjusted outcomes 
and 95% confidence intervals (CI).   
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In multivariate models, age, education, years since menopause, number of children 
breastfed, BMD, body mass index, height, weight, weight change/yr from v4 to baseline for 
calcaneus and from v4 to v2 for total hip and femoral neck, alcohol intake, walking speed, 
grip strength, calcium intake, total kcal/week from exercise, Trailmaking Part B, corrected 
visual acuity were entered into the models as continuous variables.  All other variables 
were categorical: clinic, smoking (never/former/current), walking for exercise (yes/no), 
functional impairment (yes/no), two or more falls in the year before baseline (yes/no), oral 
estrogen, vitamin D use, thiazide diuretic, steroid use (current/former/never), and arthritis 
(yes/no), fractures after age 50(yes/no), health compared to other(good/excellent vs. 
fair/poor/very poor)  and history of fracture in the mother(yes/no), tandem stand with eyes 
closed(poor/good) physician diagnosis of COPD, arthritis, hypertension, diabetes, stroke, 
angina (yes/no) and use of arms to stand up from the chair(yes/no), use of CNS active 
medication (yes/no), and depression score ≥ 6 (yes/no).  The proportionality assumptions 
of the Cox models were evaluated with Schoenfeld residuals.  Data was analyzed with 
Stata (edition 9, StataCorp, College Station, Texas) 
3.5 RESULTS 
The mean blood lead level (BLL) was 5.3 µg/dl (±SD 2.3) and ranged from 1-21 µg/dl.  
Women in the highest BLL category ( ≥8 µg/dl ) had lived more years after menopause, 
had lower body weight and BMI,  and were more likely to smoke and drink alcohol and 
less likely to take vitamin D supplements.  Neither cognitive function nor functional status 
was significantly different across BLL categories.  Women in highest BLL group had lower 
mean baseline total hip BMD compared to women in lower category (p<0.0211;Table3-1).  
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Femoral neck BMD was also lower in this group although it did not reach a statistical 
significance.  Baseline calcaneal BMD did not differ across the three groups.  
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Figure 3-1 Age adjusted annualized percentage rate of BMD decline by blood lead levels in SOF 
3.5.1 
3.5.2 
Change in Bone Mineral Density 
Women with highest blood lead levels experienced a greater rate of decline in BMD 
(Table3-2).  The annualized rate of decline in total hip BMD was 3 times higher for women 
in higher BLL category as compared to those in lower categories in age-adjusted models.  
When adjusted for other covariates, the difference in total hip BMD loss across three BLL 
categories persisted.  Results were consistent at both the femoral neck and calcaneus. 
(Figure 3-1) 
Fractures 
After an average follow up of more than 10.5 years, 163 (23%) women reported an 
incident fracture.  The incidence of non-traumatic non-spine fractures was higher among 
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women with higher blood lead levels (Figure 3-2).  The relative risk of fracture was 
greatest among women with the blood lead levels ≥ 8µg /dl (Table3- 3: Figure 3-2).  In 
age-adjusted models, women with the highest blood lead level had a 66% increased risk 
of fracture.  The association remained significant in the multivariate model where women 
with the highest blood lead level had a 74% increased risk of fracture in comparison to 
women with the lowest blood lead levels.  Women in the medium blood lead category were 
not at an increased risk of fracture.  The incidence rate of fractures /1000 woman-years 
was highest in women with  blood lead levels ≥ 8µg /dl, who had 1.6 to 1.7 times higher 
rate of incident fractures when compared with women with the lowest and medium blood 
lead levels, respectively (Figure 3-4).   
Age,  Multivariate Adjusted Non-Spine Fracture 
Hazard Ratio (HR) by Blood Lead Levels in SOF
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Figure 3-2 Age and multivariate adjusted non-spine fracture Hazard Ratio by blood lead levels. 
 
Further analysis, using blood lead levels as a continuous variable, incident 
fractures were significantly higher, in unadjusted, age and multivariate adjusted models by 
17%,13% and 18% respectively, per one standard deviation increase in blood lead levels.  
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The cumulative incidence of fracture as graphed by Kaplan Meier curves, increased over 
time in women with the highest blood lead level (Log rank test=0.038; Figure 3-5).  
3.5.3 Falls 
 
 Age, Multivariate Adjusted Falls Incidence Rate 
Ratio (IRR) by Blood Lead Levels in SOF
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Figure 3-3 Age and multivariate adjusted falls Incidence Rate Ratio by blood lead levels in SOF 
 
During the 3 year follow up period, the incidence of falls was higher among women with 
higher blood lead levels (Table 3).  The relative risk of falls was greatest among women 
with the blood lead levels ≥ 8µg /dl.  In age-adjusted models, women with the highest 
blood lead level had a 40% increased risk of fall.  The association was statistically 
significant in the multivariate model where women in the highest blood lead category were 
at 87% increased risk of falls as compared to women with the lowest blood lead level (p 
trend=0.006).  Analyzing, blood lead levels as a continuous variable, incident falls were 
not significantly higher in unadjusted and age adjusted models.  However after controlling 
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for shared risk factors, in multivariate adjusted models, risk of falls increased by 13% per 
one standard deviation increase in blood lead levels.  (Figure 3-4) 
 
3.6 DISCUSSION 
In this cohort of older women, higher blood lead levels were associated with lower total hip 
BMD, greater rate of decline in BMD and an increased risk of falls and non-spine fractures.  
We found an association with fractures and decline in BMD at blood lead levels ≥8µg/dl, a 
level previously thought to be safe.  The association with non-spine fractures was not 
explained by baseline BMD or poor cognitive or physical function.  Similarly, the 
association with falls was not explained by poor neuromuscular function.  To our 
knowledge this is the first longitudinal study to explore the association of blood lead levels 
with osteoporotic fractures, falls, and rates of decline in BMD in older women. 
Although mean U.S. national blood lead levels have decreased dramatically over 
the past 30 years, as documented by repeated National Health and Nutrition Examination 
Surveys from 1988 to 2002, lead toxicity continues to be a public health problem for older 
individuals with higher lifetime environmental lead exposure[10, 11]. More specifically, 
older women who grew up when environmental exposures were higher due to leaded 
gasoline, paint and unregulated industrial lead use, may have absorbed more lead from 
the environment in everyday life and thus have a higher body burden of stored lead[1].  
Several large epidemiological studies have found that BLL are higher in older 
people than younger adults[1, 2] the difference being more pronounced in women across 
the menopausal transition, perhaps reflecting a greater release of lead from bone 
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secondary to increased menopausal bone loss. Research studies report increases in bone 
lead with older age [12-14].  
Elevated blood lead levels may have a causative role in the pathogenesis of 
osteoporosis[15-17]. Animal studies have shown an association between increased bone 
lead concentration and lower bone mass, decreased mechanical strength and increase 
incidence of fractures[18-22].  Lead inhibits axial bone development and  decreases bone 
mass due to enhanced resorption in animal models[19]. Histomorphometric studies have 
demonstrated a significant Pb-associated decrease in length of rat femoral growth plate 
cartilage[21].  
An inverse relationship has also been documented between elevated BLL and 
skeletal development, chest circumference, and stature in children [23-25]. A longitudinal 
analysis of women with occupational lead exposure showed that vertebral BMD was 
inversely associated with BLL[26-28]. Bone mineral density was also significantly inversely 
associated with blood lead level in general population after adjusting for other factors 
associated with blood lead[29]. Hu, H. et al used  K-X-ray fluorescence (K-XRF) to 
measure lead levels in the tibia and patella on a series of twelve lead exposed male 
subjects  before and after chelation with EDTA (ethylenediamine tetraacetic acid).  K-XRF 
levels in the patella were noted to decrease more rapidly than levels in the tibia after 
cessation of lead exposure, a finding that probably reflects the greater turnover of lead in 
trabecular bone than in cortical bone[30, 31].  We found significantly higher declines 
among the women with the highest lead levels.  This observation was consistent across 
sites suggesting that lead influences both cortical and trabecular bone loss [30]. 
The effects of lead on growing bone as well as adult remodeling and age related 
osteoporosis  can predispose to fractures[32]. Lead exposure has been reported to 
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accelerate bone maturation by inhibiting the effects of parathyroid hormone-related 
peptide[33]. Accelerated maturation of bone may ultimately result in a lower peak BMD, 
thus predisposing to osteoporosis in later life [33]. A hypothetical “Pb-exposed female” 
may never reach her peak bone mineral density because of compromised growth plate 
chondrocyte activity. At menopause, increased bone turnover would accelerate the loss of 
bone mineral such that the “Pb-exposed female” would cross over a fracture threshold 
earlier in life than an unaffected individual.  In our study, baseline BMD levels were slightly 
lower among women with higher blood lead levels. 
Lead exposure could predispose to fractures because of increased risk of falls as it    
effects neuromuscular function and balance[5, 6].  Lead exposure in childhood has been 
associated with impaired  maturation of postural balance and central auditory 
processing[34-37]. Neuromotor dysfunction in lead workers has been reported at blood 
lead level as low as 12.1-17.3 (mean 14.4) µg/dl[34]. Cerebellum which controls the 
postural balance is the second most frequently involved brain region for lead deposition, 
besides hippocampus.  Cerebellar Purkinje cell damage in rats exposed to lead has been 
documented[38].  By computerized static posturography, the effect of lead on postural 
balance was examined in 49 male lead workers, with mean (range) BLL 18(7 to 36) 
µg/100 g.  As compared to healthy non-lead exposed controls, the postural sway in lead 
exposed workers with eyes open, was significantly greater in the medio-lateral (right-left) 
and anterior-posterior directions.  Similarly, the sway with eyes closed was significantly 
larger in lead workers than in controls in the medio-lateral direction.  The pattern of sway 
suggests that the anterior cerebellar lobe, vestibulo-cerebellum, and spinocerebellar 
pathway were affected by lead[39].  
Lead slows the nerve conduction velocities in peripheral nerves which could delay 
motor coordination, impair perception of vibration, light touch and position of the joints[34, 
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40]. Muscle is one of the soft tissues where lead is deposited in addition to skeletal, 
nervous, and renal tissues.  Muscle weakness and easy fatigue occur early and may be 
the only symptoms of lead exposure.  The muscle groups usually involved are the most 
active ones, such as the extensors of the forearms, wrist and fingers[41]. Blood lead levels 
as low as 8 µg/dl were associated with poorer performance on tests of visual perception, 
psychomotor speed, and manual dexterity[7].  
A negative correlation has been observed between lead and  Vitamin D[16]. Low 
Vitamin D has been linked to hip and non spine fractures and falls[42, 43].  Women with 
the highest blood lead levels in our study had higher fracture and fall risk.  Women in this 
group had significantly lower Vitamin D intake at baseline in comparison with women with 
lower blood lead levels suggesting that circulating Vitamin D levels were also lower in this 
group (Table1).  Genetic polymorphism has been identified in the vitamin D receptor 
(VDR), that can influence the accumulation of lead in bone[44]. 
There are a number of strengths to our study.  We used a prospective study design 
and studied a well-characterized cohort of community-dwelling older women, using state-
of-the-art measurements of BMD.  Follow-up was nearly complete for important outcomes 
of falls and fractures, and fractures were validated by review of radiology reports and/or 
medical records.  The analyses adjusted for a number of important covariates, including 
cognitive and neuromuscular function.  However, this study does have some limitations.  
Our participants were likely to be healthier than average community-dwelling older women 
because they were volunteers.  While we adjusted for a summary measure of cognitive 
function, it is possible that lead affects specific cognitive abilities.  Finally, our data may not 
apply to older nonwhite women or men. 
In conclusion, high BLL was associated with an increased risk of falls and fractures 
as well as greater rates of decline in BMD in older women independent of age and other 
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risk factors.  This association was found at BLL previously thought to be safe.  It is 
possible that treatment to reduce the elevated BLL could lead to a decrease in falls and 
osteoporotic fractures; clinical trials examining this hypothesis should be conducted. 
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Table 3-1 Baseline characteristics in women in SOF by blood lead levels 
Blood Lead Level  
( µg/dl) 
(N=533) 
Low 
(≤3) 
N=122 
Medium 
(4-7) 
N=332 
High 
( ≥8) 
N=79 
 
p -
value 
Age (years), mean ±(SD) 72.3 (4.3) 72.4(4.5) 73(4.5) 0.411 
Clinic, n (col %)    
     Urban  (n=205) 33(27) 131(39) 41(52) 
     Rural  (N=328) 89(73) 201(61) 38(48) 
 
0.002 
Education, years, mean±(SD) 12(3) 13(3) 13(3) 0.360 
Weight (kg), mean ±(SD) 69(13) 67(12) 65(12) 0.089 
Weight change, kg/yr mean ±(SD) 
 (v4–v2,Total hip, femoral neck) 
 
-0.14(1.0) 
 
-0.12(1.2) 
 
-0.03(1.0) 
 
0.828 
 (v4–v1,Calcaneus)  -0.04(0.85) -0.11(0.83) -0.24(0.77) 0.388 
Height (cm), mean ±(SD) 159(5.8) 159(5.6) 158(6) 0.653 
Body mass index, kg/m2, mean ± (SD) 27(4.8) 27 (4.6) 26 (4.6) 0.039 
Years since menopause, mean ± (SD) 21.3(8.2) 23(7.3) 25 (8) 0.017 
Age at menopause, yr, mean ± (SD) 49(6.3) 48(5.7) 46(6.2) 0.011 
Ever pregnant, n (%) 103 (84) 280 (84) 64 (81) 0.757 
Surgical Menopause: n (%) 20(13) 41 (13) 11(14) 0.485 
Ever breastfed, n (col %) 66(64) 181(65) 29(45) 0.014 
Smoke = n (%)      
   Never 77(63) 199(60) 32(40) 
   Past 38(31) 94(28) 27 (34) 
   Current 7 (6) 38 (12) 20 (25) 
0.000 
Pack-years smoked, mean ±(SD) 18.3(18) 27(21) 31(22) 0.010 
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Table 3-1 continued 
Alcohol (drinks /wk),mean ±(SD) 1.1 (3) 1.8 (4) 3.2(6) 0.002 
Calcium intake, (mg/wk),mean ± (SD) 4720(2498) 4575 (2793) 4574 (3592) 0.886 
Vit D supplement, n (%)     
   Never 60(50) 195(60) 56(72) 
   Past 9(8) 17(5) 4 (5) 
   Current 50 (42) 114(35) 18 (23) 
0.052 
Total # Yrs Taken Vit. D, mean ± (SD) 13(15) 10(11) 5.0(7) 0.019 
Current Estrogen use, n (%) 43(35) 113(34) 22(28) 0.511 
Current Thiazide diuretic use, n (%) 35(29) 113(34) 24(30) 0.517 
Diabetes, n (%) 14(12) 33(10) 7(9) 0.688 
Hypertension, n (%) 28(23) 100 (30) 25(32) 0.289 
Self reported health, n (%) 
    excellent /good vs. fair /poor 
 
99(81) 
 
282(85) 
 
66(83) 
 
0.493 
Functional status Impairments, 
mean±(SD) 
 
0.77(1.3) 
 
0.78 (1.3) 
 
0.59(1.1) 
 
0.506 
Incident fracture, n (%) 43(20) 140(66) 29(14) 0.469 
Any fracture after age 50, n (%) 40(33) 109(33) 22(28) 0.683 
Maternal fracture history, n (%) 33(35) 82(32) 23(36) 0.763 
Fallen in past year (≥ 1), n (%) 29(24) 75 (23) 20(25) 0.873 
Walk for exercise: n (%) 44(23) 125 (64) 26(13) 0.795 
Physical activity, past yr(kcal/week) 
mean ± (SD) 
1044(1047) 1239(1368) 1104(1234) 0.311 
Use arms to stand up from chair, n (%) 3(3) 10(3) 1(1) 0.671
     
 
 
  49
Table 3-1 continued     
Walking Speed Usual Pace (m/s) mean 
± (SD) 
1.01(0.2) 1.04(0.2) 1.03(0.2) 0.483 
Grip strength (kg) mean ± (SD) 20.6(4) 20.9(4) 20.7(4) 0.756 
Tandem stands (eyes closed), n (%) 20(16) 102(31) 26(33) 0.006 
Current Estrogen use, n (%) 43(35) 113(34) 22(28) 0.511 
Current Thiazide diuretic use, n (%) 35(29) 113(34) 24(30) 0.517 
Trailmaking B(number of seconds) 
mean ± (SD) 
116(36) 121(39) 126(44) 0.192 
Bone Mineral Density (mg/cm²):     
   Total Hip, mean ± (SD) 0.77(0.13) 0.76(0.13) 0.72 (0.12) 0.021 
   Femoral Neck, mean ± (SD) 0.65 (0.11) 0.66 (0.12) 0.62 (0.09) 0.071 
   Calcaneus, mean ± (SD) 0.41(0.09) 0.42(0.09) 0.39 (0.09) 0.145 
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Table 3-2 Multivariate adjusted Annualized Percentage Rate of bone mineral density 
decline by blood lead levels 
*MV=multivariate adjusted  
*The Multivariate model included the following: age, weight, walk speed, weight change between v4 and baseline, smoking, walk for 
exercise, Thiazide diuretic use.  Additional adjustment for clinic, education, height,  age  at menopause,  consumed alcohol in the past 
30 days, breastfed children, baseline BMD,  total kilocalories /wk from walking ,any fractures since age 50, maternal history of 
fractures, calcium intake, Vitamin D use, hormone therapy, health compared to others, functional status,  use of arms to stand up from 
a chair, Part B Trailmaking  Test  score, diabetes, hypertension, average grip strength (steroid use for calcaneus) had no effect on the 
BMD estimate . 
 Blood Lead Level  
Low (≤3µg/dl) 
(n=122) 
Medium (4-7µg/dl) 
(n=332) 
High (≥8µg/dl) 
(n=79) 
 
 BMD Decline 
(%/year) 
Mean 95%CI Mean 95%CI Mean 95%CI P trend 
Total Hip 
Age Adjusted -0.29 -0.59,0.00 -0.46 -0.64,-0.28 -0.83 -1.23,-0.44 0.104 
MV* Adjusted -0.28 -0.57,-0.00 -0.41 -0.57,-0.24 -0.74 -1.11,-0.36 0.165 
Femoral Neck 
Age Adjusted -0.16 -0.55,-0.22 -0.57 -0.80,-0.34 -0.70 -1.21,-0.18 0.150 
MV  Adjusted -0.21 -0.60,0.16 -0.59 -0.81,-0.36 -0.71 -1.21,-0.21 0.180 
Calcaneus 
Age Adjusted -0.95 -1.22, -0.68 -1.43 -1.60, -1.26 -1.55 -1.92, -1.18 0.001 
MV Adjusted -0.92 -1.23, -0.61 -1.32 -1.51, -1.12 -1.56 -2.02, -1.11 0.045 
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Table 3-3 Age and shared risk factors adjusted Hazard Ratio(95%CI) of non-spine 
fractures and Incidence Rate Ratio of falls in women in SOF by blood lead level 
 
Blood Lead Levels (µg/dl) 
 
 
 
N=533 
Low(≤3) 
N=122 
Medium(4-7) 
N=332 
High(≥8) 
N=79 
 
 
 
p-trend
Hazard Ratio of Incident Non-spine Fracture**  
 Referent HR 95%CI HR 95%CI  
Age adjusted 1.0 1.12 0.75-1.66 1.66 1.00-2.72 0.061 
MV¶ adjusted 1.0 1.10 0.72-1.67 1.74 1.01-2.98 0.059 
Incidence Rate Ratio of Falls‡ 
 Referent IRR 95%CI IRR 95%CI  
Age adjusted 1.0 1.17 0.87-1.57 1.40 0.97-2.02 0.073 
MV adjusted 1.0 1.18 0.87-1.58 1.87 1.24-2.82 0.006 
       
 
¶ Multivariate Adjusted 
**The Multivariate model included the following : age, BMI,  years after menopause, baseline total hip BMD, fractures after age 50. 
Additional adjustment for clinic, height, weight, walk for exercise, total kilocalories /wk from walking, use arms to stand up from chair, 
fallen in the past year, consumed alcohol in the past 30 days, current smoking, current calcium use, hormone therapy, ever breastfed, 
maternal fracture history, average grip strength, osteoarthritis, fair or poor health, functional status, COPD, hypertension, diabetes, 
myocardial infarction, part B Trailmaking Test score had no effect on the HR estimate. 
 
‡ Adjusted for age, weight, education, walk for exercise,  use arms to stand up from chair, fallen in the past year, consumed alcohol in 
the past 30 days, current smoking, hormone therapy, current calcium use,  average grip strength,  fair or poor health, functional 
difficulty, COPD, arthritis, h/o stroke, hypertension, diabetes,  Vit D use,  part B Trailmaking Test score, use of  benzodiazepines, 
antidepressants, narcotics and anticonvulsants,  walking speed,  balance impaired with eyes closed, corrected visual acuity, 
depression(GDSS ≥6), ever breastfed. 
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Figure 3-4 Incidence Rate of fractures/1000 woman-yr in SOF by blood lead levels 
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levels 
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4.1 ABSTRACT 
Background: Higher Blood Lead Levels (BLL) have been associated with increased all 
cause, and cardiovascular mortality in the general population and in exposed occupational 
cohorts.  The objective of present study was to determine the associations of blood lead 
levels with mortality in older women.  
Methods: 533 participants from the Study of Osteoporotic Fractures (SOF), with mean 
(±SD) age 72.5 (±4.4) years were followed from 1986-1987.  All deaths were confirmed by 
death certificates. Blood lead level was determined by graphite furnace atomic absorption 
spectrometry.  Participants were divided into two categories based on distribution of blood 
lead level into low: ≤7 µg/dl and high:  ≥8 µg/dl.  Relative hazard of total and cause 
specific mortality by blood lead categories was calculated using Cox proportional 
regression analyses. 
Results:  After 12.0± 2.9 years of >95% complete follow-up, women who died had slightly 
higher baseline mean (±SD) blood lead level 5.56 (±3) µg/dl than survivors: 5.17(±2.0) 
µg/dl (p=0.09).  After adjustment for age, women with baseline blood lead levels of ≥8 
µg/dl had 68% increased risk of all cause mortality (Hazard Ratio[HR],1.68; 95% 
confidence interval [CI] 1.10, 2.60) compared to women in low blood lead level group.  
With multivariate adjustment, women in high blood lead group had 2 fold increased risk of 
all cause mortality (HR, 2.34; [CI] 1.41, 3.87), 3 fold higher risk of cardiovascular mortality 
(HR: 3.31[CI] (1.54, 7.12), compared to women in low blood lead group.  There was no 
association of blood lead levels with mortality from cancer. 
Conclusion: Women with blood lead levels of ≥ 8µg/dl experienced increased mortality, in 
particular from cardiovascular disease, as compared to those with lower blood lead levels. 
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4.2 INTRODUCTION 
Lead is a multitargeted toxicant, effecting cardiovascular, and nervous systems.  Lead 
may contribute to a fraction of morbidity and mortality associated with these affects[1],[2, 
3]. 
An association between lead and mortality has been observed in both occupational  
and community based cohorts [4].  Results from the second National Health and Nutrition 
Examination Survey (1976-1980) and 2000 US Census and reported that blood lead level 
was an important predictor of mortality.  Individuals with baseline blood lead level 20 to 29 
µg/dl experienced 46 % increased all cause mortality, relative to those with blood lead 
level less than 10 µg/dl[1].  Furthermore an  increased risk of death from all causes, 
cardiovascular disease, and cancer was associated with blood lead levels of  5–9 µg/dl as 
compared to those with <5.0 µg/dl in NHANES III (1988-1994) [5]. Menke et al 
documented 25% increased all cause and 55% increased cardiovascular mortality in 
NHANES III (1988-1994) at  considerably lower blood lead levels: >3.62 µg/dl as 
compared to those with <1.94 µg/dl [6].  However they did not observe an association 
between blood lead and cancer mortality in this range of exposure.    
Higher blood levels have also been associated with cognitive and neuromuscular 
decline[7-9], cardiovascular[10-14] and renal effects [3, 15-17] all of which could contribute 
to an  increased risk of mortality.  The effects of blood lead levels on cancer mortality 
however,  are poorly understood [18].  In the current analysis we prospectively examined 
the association of blood lead levels to mortality in a cohort of 533 white women with mean 
age of 72.5(±4.4) (range: 68-89) years and mean blood lead levels of 5.3 µg/dl (±2.3 SD) 
(range: 1-21 µg/dl).  We hypothesized that women with higher blood lead levels will 
experience higher total and cause specific mortality. 
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4.3 
4.3.1 
4.3.2 
METHODS 
Study design and Population 
The Study of Osteoporotic Fractures (SOF) is a longitudinal cohort study that enrolled 
9704 white women from 1986 to 1988 using population-based listings in Baltimore, MD; 
Minneapolis, MN; Portland, OR; and the Monongahela Valley near Pittsburgh, PA.  To be 
eligible to participate, women had to be aged 65 years or older and ambulatory. 
The lead ancillary study was conducted in 1990-1991 in 533 white women aged 
65-87 years enrolled in SOF at either the University of Pittsburgh or University of Maryland 
clinics.  Initially, we  examined the correlates of blood lead and the association of blood 
lead level to cognitive function [19]. We found a relationship between  higher blood lead 
levels and worse cognitive function as measured by the part B of Trailmaking Test, but this 
association was confined to the rural SOF clinic [19, 20].  In the current paper, we extend 
the lead study to mortality outcome.  The protocol and consent forms were approved by 
the institutional review boards at the participating institutions.  All women provided written 
informed consent. 
Other Measurements 
Potential confounders of the association between blood lead levels and mortality were 
identified and adjusted for Sociodemographic factors (age, study site/clinic, education), 
smoking history, alcohol consumption (past 30 days), and physical activity from walking, 
medication use (including hormone therapy, thiazide diuretics, calcium supplements, 
vitamin D supplements), and time since menopause,  children breastfed, weight loss since 
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age 50, health status compared to others, were determined by an interview–administered 
questionnaire. 
Health impairment data included cognitive impairment, assessed as scores on 
Trailmaking Part B, functional status impairment, and depression as 6 or more depressive 
symptoms on the 15-item Geriatric Depression Scale Shortened.  Prevalent chronic 
conditions such as diabetes, hypertension, arthritis, stroke, heart murmur, angina, EKG 
abnormality, congestive cardiac failure, enlarged heart, were defined as self-report of the 
condition previously diagnosed by a physician.  Height and weight were obtained using a 
Harpenden stadiometer (Holtain Ltd, Crymych, UK) and a standard balance beam, 
respectively, and body mass index (BMI) was calculated as weight divided by height 
squared (Kg/m2).  Waist to hip ratio was determined.  Systolic and diastolic blood pressure 
was measured by manual mercury sphygmomanometer.  Physical function was assessed  
including grip strength measured as average of right and left using an adjustable hand grip 
dynameter in Kg (Preston Grip Dynameter; Takei Kiki Kogyo, Tokyo, Japan), walking 
speed (second /6 meters). 
4.3.3 Mortality 
The methods of determining deaths in SOF have been published[21, 22]. Participants were 
contacted every 4 months by postcard over 12(±3) years of follow-up.  These contacts are 
>95% complete.  Deaths were confirmed by death certificates, and, when available, 
hospital discharge summaries were obtained.  The underlying cause of death was coded 
by a clinical epidemiologist using the International Classification of Diseases, Ninth 
Revision, Clinical Modification, and categorized as due to cardiovascular disease (CVD) 
including all diseases of circulatory system except those involving veins and lymphatics 
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[ICD-9-CM codes 401 to <405, 410 to <415, 425,428, 429.2, 430 to <439, 440 to <445, 
and 798]; coronary heart disease (CHD) including deaths due to Ischemic heart disease,  
myocardial infarction and sudden death [ICD-9-CM 410-414]; atherosclerotic Cardiac 
disease [ICD-9-CM 410-415, 798,  427.5, 428,  429.2]; cancer [ICD-9-CM codes 140 to 
239] and  all other deaths. 
4.3.4 
4.3.5 
Blood lead measurements 
A 5.0 ml sample of whole blood was drawn into Vacutainer tubes (BD Vacutainer Systems, 
Rutherford, New Jersey).  Blood samples were analyzed at the Clinical Chemistry 
Laboratory of the University of Maryland, certified for the analysis of lead in blood by the 
Occupational Safety and Health Administration and Centers for Disease Control and 
Prevention, and documents a lower limit of detection for lead of 1µg/dL.  BLL were 
determined by graphite furnace atomic absorption spectrometry (AAS model 5100, HGA 
with Zeeman Effect background correction: Perkin Elmer, Norwalk, Connecticut).  To 
determine intralaboratory measurement variability in lead level and the stability of samples 
over 1year, 100 samples (50 from each clinic) were drawn from randomly selected women 
during a clinic visit, one year later. The intraclass correlation coefficient for the duplicates 
was 0.88.  Mean values of 4.76 µg/dl (range, 1-13 µg/dl) and 4.67µg/dl (range, 1-12 µg/dl) 
were obtained for the first and second determinations, respectively[19] 
Statistical analyses 
Participants were divided into two categories, corresponding to the upper 15th and lower 
85th percentiles of the distribution of blood lead variable.  Thus the two groups were : low ( 
≤7 µg/dl, n=454), and high( ≥8  µg/dl, n=79)[19].  To compare baseline characteristics by 
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mortality status, we used Chi-square tests for categorical variables and, t-tests for 
continuous variables.  Two-tailed p-values were used for all tests, at 5 % statistical 
significance.  We used Cox proportional hazard regression analysis to estimate the 
Hazard Ratio (HR) of mortality and 95% confidence interval (CI).  Women in low category 
(≤ 7µg/dl) of blood lead level formed the reference group for all analyses.  Separate 
models were analyzed for all cause and cause specific mortality.  We classified the CVD 
associated mortality into two further subgroups: deaths due to coronary heart disease 
(CHD), and due to atherosclerosis. 
In multivariate models, we simultaneously analyzed blood lead levels and other 
potential risk factors.  We assessed variables for inclusion, based on documented 
association in the literature and biological plausibility.  We organized variables into 9 
related groups, including 1) demographic factors (age, education, clinic),  2)anthropometric 
measures (BMI, waist hip ratio, weight loss since age 50)  3) lifestyle factors(smoking, 
drink alcohol, walk for exercise),  4) physical functions (average grip strength, walk speed) 
5)health status (health compared to others, depression, functional limitation), 6)functional  
performance (Trailmaking part B, depression),  7) self reported medical history ( 
hypertension, diabetes, stroke, angina, heart enlargement, congestive cardiac failure, EKG 
abnormality),  8) medication and supplement use (hormone therapy, Vitamin D, calcium 
and thiazide diuretic),  and 9)reproductive factors (years after menopause, ever breastfed). 
A forward stepwise selection process was used to add or remove potential covariates from 
the multivariate regression models (exit criteria: p>.20).  Sequential models were analyzed 
in which all variables in one group were allowed to enter in a stepwise regression based 
on p- value at each step.  The next model began with the significant variables remaining 
from the previous model.  Then a new group of variables was allowed to enter, using the 
stepwise entry procedure, for successive groups of variables, until a final model of 
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significant variables was selected.  We computed overall and age-adjusted mortality and 
95% confidence intervals.  
In multivariate models, age, education, years since menopause, clinic, children 
breastfed, BMD, body mass index, weight, weight change from age 50, alcohol intake, 
walking speed, grip strength, calcium intake, waist hip ratio, Trailmaking Part B, were 
entered into the models as continuous variables.  All other variables were categorical: 
smoking (never/former/current), walking for exercise (yes/no), functional impairment 
(yes/no), oral estrogen, vitamin D use, thiazide diuretic, (current/former/never), health 
compared to other(good/excellent vs. fair/poor/very poor)  and physician diagnosis of 
hypertension, diabetes, stroke, angina (yes/no) EKG abnormality, heart murmur, enlarged 
heart , congestive cardiac failure  and  depression score ≥ 6 (yes/no).  The proportionality 
assumptions of the Cox models were evaluated with Schoenfeld residuals.  We plotted the 
cumulative hazard of fractures in the two BLL groups over the follow-up period by Kaplan- 
Meier Survival graphs.  Data was analyzed with Stata (edition 9, StataCorp, College 
Station, Texas) 
4.4 RESULTS 
The mean blood lead level was 5.3 µg/dl (± 2.3 SD) and ranged from 1-21 µg/dl.  The 
number of women who died was 123 (23% of the participants) over mean follow up time of 
12.03 (±3.0) years.  Table 1 summarizes characteristics of this cohort by survival status.  
Women who died had slightly higher mean (±SD) blood lead levels; 5.56(±3) µg/dl than 
survivors: 5.17 (±2.0)  µg/dl (p=0.09).  Women who died were older and had lived more 
years after menopause.  The same group had slower walking speed, lower grip strength, 
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worse functional status, and cognitive test scores and reported a higher proportion of 
hypertension and current smoking.  A lower proportion of women who died reported 
current and past hormone use.  Self reported history of angina, heart attack, 
electrocardiogram abnormalities and congestive heart failure all were higher in this group 
(Table4-1). 
Hazard Ratio(HR) of Age, Multivariate adjusted 
All Cause Mortality by Blood Lead Levels in SOF
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Figure 4-1 Age and multivariate adjusted all cause mortality in women in SOF by blood lead levels 
 
High blood lead levels were associated with increased all cause mortality after age 
adjustment (Table 4-2).  Women with baseline blood lead level of ≥ 8 µg/dl had a 68% 
increased risk of age-adjusted all cause mortality (Hazard Ratio [HR] =1.68; 95% 
confidence interval [CI] 1.10, 2.58) (p=0.018) compared to women in low blood lead level 
group.  After multivariate adjustment, women in high blood lead group had a 2 fold 
increased risk of all cause mortality (HR=2.33; 1.41, 3.87) (p=0.001).  The cumulative 
incidence of all cause mortality as graphed by Kaplan Meier curves, increased over time in 
women with blood lead level ≥ 8 µg/dl.  (Figure 4-3).  
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Figure 4-2 Age and multivariate adjusted Cardiovascular disease mortality in women in SOF by blood 
lead levels. 
 
In cause-specific mortality analysis, increased mortality was predominantly due to 
cardiovascular disease.  The multivariate adjusted hazard ratios (95% CI) for CVD 
mortality for high versus the low blood lead level were 3.31(1.54, 7.12), 8.66(2.82, 26.56), 
3.93 (1.48, 10.44), respectively, for cardiovascular (CVD), coronary heart disease (CHD), 
and atherosclerotic disease mortality respectively.  Association of blood lead and mortality 
from cancer and other causes was not significant.  (Table 4-3). 
4.5 DISCUSSION 
Blood lead levels were an important predictor of all cause mortality in a cohort of 
community dwelling older women.  Mortality was significantly higher in women with blood 
lead levels of ≥8 µg/dl as compared to those with lower blood lead level. Our results are 
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consistent with earlier studies based on occupational cohorts [4, 14, 23, 24] and NHANES 
II and III[5, 6, 12, 25].  
Despite declines in blood lead levels during the past 30 years, environmental lead 
exposure continues to be a public health concern[3] . Initiated during the 1920s, the use of 
organic lead as gasoline additive has been phased out in US since 1976.  Once released 
as combustion exhaust, particulate lead persists in air, water, and soil.  Lead is a 
multitargeted toxicant, causing effects in cardiovascular, renal and nervous systems and 
may contribute to a fraction of morbidity and mortality associated with these effects.  
Lustberg and Silbergeld evaluated the association of lead exposure and mortality in the 
United States from analyses of NHANES II (1976-1980) [12].  Individuals aged 30 to 74 
with blood lead levels of 20-29 µg/dl experienced 46% increased all-cause, 39% increased 
cardiovascular and 68% increased cancer mortality compared with those with blood lead 
levels of less than 10 µg/dl.  Individuals with blood lead levels 10-20 µg/dl did not have 
higher risk of mortality.  
Schober et al. analyzed mortality data for individual’s ≥ 40 years of age in the 
NHANES III (1988-1994).  Blood lead levels of 5-9 µg/dl were associated with a 24 % 
increased risk of death from all causes, 20% increased cardiovascular , and 44% 
increased risk of cancer mortality compared to those with < 5 µg/dl [5].  In a follow-up 
paper from the NHANES III data,  participants in the highest tertile (≥ 3.6 µg/dl) of blood 
lead  had 25% and 55% increased  risk of all-cause and cardiovascular mortality, 
respectively compared with those in the lowest tertile (<1.94 µg/dl). However, no 
association between blood lead level and cancer mortality in this range of exposure was 
reported. We did not observe an association between all cause mortality and blood lead 
level until 8µg/dl[6].  Jemal et al (2002) reported a threshold level of blood lead levels at 24 
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µg/dl with cancer mortality, limited to white women in dose response analysis.  The range 
of Blood lead level that we studies was 1-21 µg/dl.  
The increased cardiovascular mortality risk may reflect an effect on sub-clinical 
cardiovascular risk factors for disease.  As part of NHANES III, an increased risk of 
peripheral arterial disease, hypertension and renal dysfunction was observed in 
populations with an average blood lead level of 2 µg/dL[3, 11, 15, 26, 27]. For example, 
the odds ratio of diastolic hypertension was 8.1 comparing women with a blood lead level 
of 4.0-31.1 µg/dL to women with lower blood lead levels of 0.5-1.6 µg/dL.  Other analyses 
support an association between blood lead levels and cardiovascular disease [10, 11, 28-
31],  renal function impairment [15, 32-37], increased blood pressure[27, 38, 39], an 
association which is biologically plausible[40-45]. Increase in blood pressure and renal 
damage have been observed after induction of lead exposure in rodent models[41-45].  
Alterations in signal transduction that involve renal pathways (eg, angiotensin and 
vasopressin) have been reported in animal models[46-48].  Mechanisms, by which lead 
may increase cardiovascular risk, include effects on neuromuscular and neuro-humoral 
regulation of vascular function, alteration in sodium transport, and alterations in calcium 
regulation [6, 7, 11, 26, 30, 31, 49-52].  
Lead is a toxic metal and categorized as probably carcinogenic to humans (Group 
2A IARC 2004)[53, 54].  Association between occupational lead exposure and cancers of  
brain, stomach, kidney and lung have been reported [55-57]. However among non 
occupational cohorts, there has been little evidence of an association between blood lead 
and cancer mortality. Individuals with mean blood lead levels 10-19 µg/dl in the  NHANES 
II(1976-1980) did not have increased risk of cancer mortality , when compared to those 
with blood lead levels <10 µg/dl.  Our results are consistent with the observation.  A higher 
risk of cancer deaths was only observed in with  blood lead level > 20µg/dl[12].  Individuals 
  66
with mean blood lead levels <10 µg/dl in the  NHANES III(1988-1994) did not have 
increased risk of cancer mortality[6].   
There are several strengths to our study; we used almost 95% complete 
adjudicated mortality events.  There was strict quality control in data collection as 
physician adjudicator confirmed all the events.  The reliability of measurement of BLL was 
optimum and we controlled for a number of risk factors.  This study has several limitations. 
Participants were limited to older Caucasian women, and the findings may not apply to 
men or nonwhite women.  Indices of cumulative lead exposure (such as bone lead levels) 
were not available and thus we could not examine cumulative lead levels with mortality.   
In conclusion, our study extends the findings of higher mortality from occupationally 
exposed cohorts to community dwelling elderly women.  An increased mortality risk, 
especially cardiovascular disease was found at blood lead levels >8 µg/dL, well below the 
current OSHA action level of 50 µg/dL.  Our results, confirmed in other cohorts, suggest 
that the action levels of blood lead level need to be lowered.  
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Table 4-1 Baseline Characteristics of Women in SOF by survival status  
 
Died Survived   
Characteristic by survival status/mortality N=123 N=410 P value 
Blood lead level(µg/dl), mean ±(SD) 5.56±3 5.17±2 0.093 
Age (years), mean ±(SD) 72 ± 4 70.0±4 0.000 
Clinic, n (row %)    
     Urban     38(19) 167(81) 0.002 
     Rural         85(26) 243(74)  
Body mass index(kg/m2) ), mean ± (SD) 26.2±5 26.8±5 0.164 
Waist-hip ratio, mean ± (SD) 0.82(0.07) 0.81(0.06) 0.074 
Education(years), mean±(SD) 12.4±3 12.4±3 0.811 
Alcohol (drinks /wk),mean ±(SD) 1.92±5 1.84±4 0.840 
Smoke, n (col %)   
   Past 37(30) 122(30) 
   Current 25(20) 40(10) 
 
0.005 
Years since menopause, mean ± (SD) 25±7.6 22 ±7.6 0.001 
Hypertension, n (%) 47(39) 106(26) 0.007 
History of  
     Abnormal EKG, n (%) 
    Stroke, n (%) 
 
27(24) 
6(5) 
 
58(15) 
11(3) 
 
0.004 
0.205 
    Angina, n (%) 21(18) 36(9) 0.011 
    Heart attack, n (%) 18(16) 21(5) 0.000 
    Congestive heart failure, n (%) 15(4) 4(1) 0.021 
Diabetes, n (%) 14(12) 38(10) 0.40
    
7 
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Table 4-1.  Continued 
 
   
Estrogen use, n (%) 
       Past 
       Current 
 
18(15) 
9(8) 
 
93(23) 
50(12) 
 
0.031 
Vit D supplement use, n (%)    
   Never 78(65) 233(58) 0.133 
   Past 9(8) 12(5)  
   Current 33(28) 149(37)  
Self reported health, n (%) 
  (Excellent /good vs. fair /poor) 
27(22) 59(14) 0.046 
Functional status Impairments, 
mean±(SD) 
1.1±2 0.66±1 0.003 
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 Table 4-2 Relative Hazard (95% CI ) of All Cause Mortality in women in SOF by Blood Lead levels 
 
¶ Multivariate Adjusted 
**The Multivariate model included the following: age, education, waist hip ratio, smoking, health compared to others, walk speed, 
hypertension, thiazide diuretic use, EKG abnormality, and history of congestive heart failure. 
Additional adjustment for clinic ,  years after menopause,  weight,  weight loss since age 50,  walk for exercise,  consumed alcohol in 
the past 30 days,  current calcium use, hormone therapy, ever breastfed,  average grip strength,  fair or poor health,  functional status, 
diabetes, myocardial infarction, angina, enlarged heart, heart murmur, stroke,  depression,  part B Trailmaking Test score, vitamin D 
use, had no effect on the HR estimate. 
Age Adjusted  Multivariate Adjusted*  
 
Blood Lead Level 
 
Hazard 
Ratio 
95% CI p-value Hazard 
Ratio 
95% CI p-value 
(≤7 µg/dl)n=96 1.0 (referent) 1.0 (referent) 
 
 (≥8 µg/dl) n=27 
 
1.68 
 
(1.10, 2.6) 
 
0.018 
 
2.33 
 
(1.41, 3.87) 
 
0.001 
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 Table 4-3 Relative Hazard (95% CI) of Cause Specific Mortality in women in SOF by Blood Lead 
levels 
Cause of Death Deaths  Blood lead level  
  (≤7µg/dl) (≥8 µg/dl) Pvalue 
1.  Cardiovascular Disease 54    
     Age Adjusted   1.0 1.89 (0.01-3.50) 0.046 
    **Multivariate Adjusted  1.0 3.31(1.54-7.12) 0.002 
        Coronary Heart Disease 23    
       Age Adjusted   1.0 3.16 (1.30-7.50) 0.009 
       §Multivariate Adjusted  1.0      8.66 (2.82-26.56) 0.000 
        Atherosclerosis  30    
       Age Adjusted  1.0 2.51(1.15-5.50) 0.021 
       ‡Multivariate Adjusted  1.0 3.93(1.48-10.44) 0.006 
2.  Cancer  38    
    Age Adjusted   1.0      1.60(0.73-3.50) 0.236 
    $Multivariate Adjusted  1.0 2.13(0.88-5.18) 0.094 
3.  All Other Deaths 31    
    Age Adjusted   1.0 1.43(0.59-3.50) 0.492 
    ©Multivariate Adjusted  1.0 1.78(0.62-5.08) 0.283 
     
Notes: ICD9 Code: 
• 390-448: deaths due to CVD : Including all diseases of circulatory system except those involving veins and lymphatics   
• 410-414: deaths due to CHD:  Ischemic  Heart Disease:  Including MI and sudden death 
• 410-415 ,798,427.5,428,429.2:  deaths due to ASH: Atherosclerosis Cardio disease  
• 140-239: deaths due to cancer. 
• All other Deaths: Non CVD and non cancer deaths 
 
**CVD: The Multivariate model included the following: age, education, waist hip ratio, smoking, health compared to others, walk speed, 
hypertension, thiazide diuretic use, EKG abnormality and history of congestive heart failure.  
Additional adjustment for clinic ,  years after menopause,  weight,  weight loss since age 50,  walk for exercise,  consumed alcohol in 
the past 30 days,  current calcium use, hormone therapy, ever breastfed,  average grip strength,  fair or poor health,  functional status, 
diabetes, myocardial infarction, angina, enlarged heart, heart murmur, stroke,  depression,  part B Trailmaking Test score, vitamin D 
use, had no effect on the HR estimate 
 
§CHD: The Multivariate model included the following : age, weight,  waist hip ratio, health compared to others, walk speed, diabetes 
hypertension, thiazide diuretic use, years since menopause, calcium use, and history of congestive heart failure, functional status  
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Table 4-3 Continued 
 
Additional adjustment for clinic,  years after menopause,  weight loss since age 50,  walk for exercise,  consumed alcohol in the past 
30 days,  current calcium use, hormone therapy, ever breastfed,  average grip strength,  fair or poor health,  functional status, 
diabetes, myocardial infarction, angina, enlarged heart, heart murmur, stroke,  depression,  part B Trailmaking Test score, vitamin D 
use, had no effect on the HR estimate 
 
‡ Atherosclerosis: The Multivariate model included the following: age, weight loss since age 50, waist hip ratio, health compared to 
others, hypertension, diabetes, years since menopause, calcium use, hormone use, and history of heart attack, functional status. 
Additional adjustment for clinic,  walk for exercise,  consumed alcohol in the past 30 days,  current calcium use, hormone therapy, ever 
breastfed,  average grip strength,  fair or poor health,  functional status, diabetes, myocardial infarction, angina, enlarged heart, heart 
murmur, stroke,  depression,  part B Trailmaking Test score, vitamin D use, had no effect on the HR estimate 
 
$Cancer  Deaths: The Multivariate model included the following : age, clinic,  hypertension,  diabetes, years since menopause, 
functional status, walk for exercise, part B Trailmaking Test score, smoking, hormone therapy. 
 
© All Other Deaths: The Multivariate model included the following: age, clinic, hypertension, diabetes, years since menopause, 
functional status, and walk for exercise, part B Trailmaking Test score, smoking, hormone therapy. 
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Figure 4-3 Kaplan-Meier Cumulative Mortality Hazard Function in women in SOF by Blood Lead Levels 
 
Fig 1.  Kaplan-Meier cumulative Mortality Hazard Function in women in SOF by blood lead 
levels. 
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5.1 ABSTRACT 
Background: Lead is known to alter performance on a variety of cognitive measures.  
Whether long term occupational lead exposure modifies age related cognitive decline, and 
if specific cognitive domains are affected, is of recent public health concern. 
Methods: We completed a follow-up study to evaluate the association of lead biomarkers 
with cognitive function in 89 lead exposed and 52 un-exposed blue collar male workers 
from Eastern Pennsylvania.  The workers had been previously assessed in 1982 as part of 
a larger cross-sectional study.  For the current study, we measured tibia lead levels by x-
ray fluorescence and collected blood lead levels.  A battery of cognitive tests was 
completed in the original 1982 evaluation, and the current assessment repeated the same 
battery of tests.  The test battery assesses five major cognitive domains: psychomotor 
speed, spatial function, executive function, general intelligence and memory as well as a 
composite score.  Comparisons were made between workers.  In addition, the effect of 
age, <55 years or greater, on cognition, exposure and lead biomarkers was analyzed, 
adjusting for education, income, marital status, years of employment, smoking and alcohol 
intake.    
RESULTS:  The mean (±sd) age of workers was 54(9) and they were employed for an 
average of 25(8) years.  Controls had an average age of 55(9) years and were employed 
for an average of 27(7) years.  For exposed workers, the median (±Inter quartile range) 
bone lead level was 57(20-86) µg of lead/g of bone mineral (µg/g) and 8(4-15) µg/dl blood 
lead respectively.  For controls, the median (Iqr) bone lead level was 12(-8 to 32) µg/g, 
and 3(3-4) µg/dl of blood lead.  Compared to controls, exposed workers, had higher bone 
lead levels which were associated with lower total cognitive scores in 2004 (p<0.05) as 
well as lower spatial function scores (p<0.001).  In exposed workers age 55 and older, 
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higher bone lead levels were associated with lower test scores for total score (p<0.001) 
spatial function and general intelligence domains (p<0.001 both).  In exposed workers, 
higher bone lead levels also predicted cognitive decline in the overall total score, spatial 
(p<0.001 for both), and executive function (p<0.05) from 1982 to 2004.  For total cognitive 
score in exposed workers, the decrement associated with an increase of 50 µg/g bone 
lead was comparable in magnitude to the cognitive decline associated with 5 years of age. 
Conclusions: Independent of recent lead dose, retained bone lead from cumulative 
exposure may have persistent effects on cognitive function.  A portion of age related 
decrement in cognitive function in this population may be associated with earlier lead 
exposure. 
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5.2 INTRODUCTION 
Lead is a highly prevalent neurotoxicant  that bio-accumulates in bone with a half life of 
25-30 years[1-4].  Lead is associated with decreased cognitive function in both children 
and adults[5-7]. In adults lead exposure has been associated with decreased  
performance  in psychomotor speed, manual dexterity, memory, and learning ability[8]. 
Whether cumulative occupational exposure to lead causes progressive decrements in 
specific cognitive domains with aging, has been of recent concern[9]. The bio-markers that 
estimate content of lead in the body are, blood levels that estimates recent exposure or 
endogenous recirculation, and bone levels, which  estimate cumulative dose[10-12]. 
The skeleton is the major repository for lead within the body, sequestering up to 95 
percent of lead  where it can be measured by X-ray fluorescence (XRF) [2, 3, 13-16].  
Lead may be mobilized from skeletal stores when there is high bone turnover, such as in 
age related osteoporosis and can be an endogenous source of recirculation[4].  Blood lead 
concentrations are presumed to reflect exposure received in the most recent few months, 
but actually it is a composite index that reflects the equilibrium between ongoing exposure, 
excretory loss, and movement of lead  from bone[3, 17]. 
Occupational studies have reported that lead adversely affects cognitive 
performance as a function of recent and cumulative dose[18, 19] Past cumulative 
absorption of lead has been associated with longitudinal declines in verbal memory and 
learning, visual memory, and executive function. A more recent study of organolead 
workers reported significant neurological  and structural decrements with higher tibia lead, 
as long as 18 years after occupational exposure stopped[8]. It is postulated that 
neurological lesions associated with bone lead are persistent and  progressive[20]. This is 
consistent with animal evidence suggesting that lead can cause cell death from oxidative 
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stress or changes in cell structure, such as neurofibrillary tangles[21-24]. Lead could 
disrupt the myelination that normally continues in the fifth to sixth decade of life in cortical 
association areas that have large axonal projections[25].  
We report the results of a follow-up evaluation of an earlier occupational study 
conducted in 1982 where blood lead was predictive of poorer neurobehavioral test scores 
in psychomotor speed.  To determine whether long term exposure to lead as an adult can 
cause progressive changes in cognitive function with aging, we conducted a follow up of 
89 lead workers and 52 non-exposed controls (from the original cohort enrolled in 1982).  
We hypothesized that workers with higher bone and blood lead levels would have a 
greater risk of cognitive decline with age. 
5.3 
5.3.1 
METHODS 
Study population  
The Lead Occupational Study was a cross sectional study conducted in1982 with 288 
white lead exposed male workers and 181 controls.  Lead exposed workers were drawn 
from company lists at three lead battery plants located in Eastern Pennsylvania.  
Unexposed control workers were drawn from a neighboring factory that manufactured 
truck chassis.  The control subjects had no documented exposure to lead or other 
neurotoxic chemicals[26]. Inclusion criteria for the initial evaluation were; employment for 
at least one year, English speaking Caucasian male, 18-60 years of age.  
The 1982 Lead study compared cognitive function in exposed and control workers 
with the Pittsburgh Occupational Exposures Test (POET) battery [26-29].  The POET 
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consists of a battery of cognitive tests that was designed to assess performance across 
different cognitive domains.  A factor analysis from the 1982 study revealed five primary 
cognitive domains: psychomotor speed, spatial function, executive function, general 
intelligence, learning, and memory.  
At the initial evaluation in 1982 (v1), the exposed workers had a mean age, and 
education and employment of 35, 11 years, respectively.  The control workers had a mean 
age, education of 40, 12 years respectively.  The mean blood lead levels in exposed and 
controls workers was 40 µg/dl and 7.2 µg/dl respectively.  After controlling for age, 
education, and income, the exposed workers scored  significantly less on tests of 
psychomotor speed with the differences limited to older workers[26, 27]. The original 
income, alcohol use and blood lead levels data for these workers was de-identified and not 
available for the current. 
In the current paper we present results on the cognitive measures for 89 of the 
original lead exposed participants (31% of the original exposed at v1) and 52 of the non-
exposed controls (29% of the original non-exposed at v1).  The same test battery that was 
administered in 1982 was re-administered in 2004.  In addition to blood lead levels, tibia 
lead measurements with XRF were completed.  The protocol and consent forms were 
approved by Institutional Review Board of the University of Pittsburgh, and all participants 
provided written informed consent.  The University of Pittsburgh Radiation Safety 
Committee approved the XRF protocol.  Subjects were paid a fee to travel to Pittsburgh for 
the current evaluation. 
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5.3.2 
5.3.3 
Data collection 
Data was collected at the University of Pittsburgh.  All subjects completed baseline testing 
in a standard order: standardized questionnaire to assess demographic and background 
information, blood pressure, height, weight, cognitive testing, and XRF measurement.  
Cognitive test battery 
The domains included psychoMotor speed:  Trail making part A: Administered in 
standard fashion, Embedded Figures: Mean time to find correct solutions on the Boston 
Embedded Figures test (see below).  Grooved Peg board: Time to insert 25 pegs in a 
pegboard (first with the dominant hand and then with the non dominant hand).  Spatial 
Function:  Visual Reproductions: Immediate reproductions of the Wechsler Memory Scale 
(WMS) in which subjects were asked to copy each of the designs.  Delayed recall of the 
Visual Reproductions was assessed 30 min later when subjects were unexpectedly 
required to reproduce them from memory.  Boston Embedded Figures; On each trial, a 
relatively simple line drawing was shown along with four complex patterns.  The subject 
was asked to identify the matching pattern.  Time to complete this test was coded under 
the Psychomotor Speed Domain (see above).  The Wechsler Adult Intelligence Scale 
Revised (WAIS-R) Block design subtest:  required subjects to reproduce a series of 
increasingly difficult geometric designs using red and white blocks.  Scoring reflects both 
accuracy and speed in correctly reproducing the designs.  Executive Function:  Trail 
Making Part B was administered in the standard fashion.  WAIS-R Digit Span and Digit 
Symbol Substitution subtests were administered in the usual manner. General 
Intelligence:  WAIS-R Information, Picture Completion, and Similarities were administered 
in the standard fashion.  Learning and Memory: Verbal Paired Associative Learning. 
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Each of the 10 pairs of unrelated nouns was read to the subject while presented visually.  
Subjects were tested by presenting the first word of each pair as a retrieval cue. Delayed 
verbal recall of the 10 pairs was assessed 30 min later by cueing subjects with the first 
word of each pair.  Symbol Digit Paired Associate learning: seven symbols, each paired 
with a single digit, were presented one at a time for 3 seconds.  Delayed symbol –digit 
recall was assessed 30 min later by presenting each of the 7 symbols and subjects were 
asked to recall the digit paired with the symbol. Incidental Recall of the symbols from the 
WAIS-R Digit Symbol Substitution Test was queried.  A Recurring Words Test asked 
subjects to look at a series of four letter words and recall which ones were previously 
presented. 
5.3.4 Biological measurements 
Bone lead levels Bone lead concentration was obtained with the conventional K-XRF 
technique employing 88.025 KeVs from 109Cd induced Pb K-shell x-ray fluorescence, 
measured with a backscatter counting geometry.  A 30-minute measurement was taken at 
the midshaft of the left tibia after washing with a 50 percent solution of isopropyl alcohol.  
The tibial midshaft was taken as the midpoint between the tibial plateau and the medial 
malleolus.  The K-XRF beam collimator was sited perpendicularly to the flat bony surface 
of the tibia.  Tibia lead level was expressed in units of µg lead per gram of bone mineral, 
(hereafter referred to as µg/g).  To maintain quality control, a check standard (Lucite 
encased lead target) was run prior to subject measurement.  The University of Pittsburgh 
Radiation Safety Committee approved the XRF protocol. 
Blood lead levels A blood sample for lead measurement was taken in a special lead-free 
tube containing ethylene-diamine-tetra-acetic acid and was determined using atomic 
absorption spectrophotometry conducted by the Central Laboratory Service Inc., an 
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affiliate of the University of Pittsburgh Medical Center.  Detection limits for this laboratory 
are 3 ug/dl.  
5.3.5 
5.3.6 
Covariates:   
Information about age (years), cigarette smoking history (current, never), family income, 
and education was obtained from the interview.  Information about height, weight, body 
mass index (BMI, calculated as weight in kilograms divided by the square of height in 
meters) systolic and diastolic blood pressure and alcohol use (amount consumed per 
week) was obtained from the physical examination and examination-associated 
questionnaire, respectively.  Income was categorized as >40,000 or ≤40,000$/ year.  A 
dichotomous education variable was created on the basis of the number of years of 
education reported by the participant (0-11 years: <high school; 12 years or greater = 
completed high school or higher).  
Statistical analyses 
Baseline characteristics by exposure status were compared by Chi-square test for 
categorical variables and either 2-sample t-test or Wilcoxon Mann Whitney-U test for 
continuous variables. Interquartile ranges were the difference between values at the 75th 
and 25th percentile levels of a given distribution for non-normal variables (bone lead, blood 
lead and drinks/wk). Two-tailed p-values were used for all tests, at 5 % statistical 
significance.  Participants were analyzed by exposure status i.e., exposed (n=83) 
compared to controls (n=52).  We further divided the exposed workers into two age 
groups: <55 years (n=54), ≥55 (n=29) for age stratified analysis.  The 20 cognitive test 
scores were summarized into five cognitive domain scores (based on prior factor analysis) 
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to minimize multiple comparisons [26, 27]. All cognitive tests were z-transformed and were 
standardized for direction so that a negative regression coefficient indicated worse 
performance with increasing lead levels. 
Linear regression was used to determine the association of cognitive function with 
lead biomarkers. To determine cross sectional association of lead biomarkers with 
cognition at v2, we used regression analysis stratified by exposure. The exposed group 
was stratified further by age into <55 and≥ 55 years. To predict cognitive decline from v1 
to v2 we used linear regression analysis stratified only by exposure.  We ran separate 
models for each cognitive domain first with covariates (Model1), sequential adjustment for 
bone lead (Model 2) , removed bone lead and added blood lead(Model 3), and blood and 
bone lead together (Model 4).  
We also used linear regression to analyze association lead levels at v2 with 
change in scores from v1 to v2. This was based on the assumption that half life of tibia is 
20-30 years and it would not substantially change between the two visits (22 years). A new 
change variable was created as a v2 minus v1 score for all the domains and the total 
cognitive score.  In these models, 
We controlled for baseline score for respective domains at v1 in addition to the 
covariates.  We did not analyze association of blood lead levels in the change score 
models.  A Huber White Sandwich estimator of variance was used with robust regression 
to construct valid standard errors.  In multivariate models, we simultaneously analyzed 
lead biomarkers and other potential risk factors.  We included variables which were 
significantly associated with respective outcomes or lead exposure either reported in 
literature or from preliminary univariate analysis.  Age (years), BMI, alcohol intake 
(drinks/wk), duration of employment (years), years since last worked, blood pressure 
(systolic blood pressure divided by the diastolic blood pressure) were entered as 
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continuous variables. All other variables were categorical: income (≤ 40k/yr vs. >40), 
smoking (yes/no) education (>=12 years, <12years), and marital status (unmarried / 
married).  To assess interactions between lead and other covariates, we created 
multiplicative interaction terms between the lead and other covariate variables and 
included them in the model along with the main effects.  Examination of added variable 
plots and partial residual plots suggested five influential points which were statistically 
controlled. Data was analyzed with Stata (edition 9, StataCorp, College Station, Texas). 
5.4 RESULTS 
The mean (SD) age of exposed workers was 54(9) and was employed for 25(8) years.  
The mean age of controls was 55(9) years and they were employed for 27(7) years. The 
median (±Inter quartile range) of bone lead level was 57(20, 86) µg/g in exposed and 12(-
8, 32) µg/g in controls, respectively (p=<0.000).  The median (±Inter quartile range) of 
blood lead level was 12 (8, 19) µg/dl, in exposed and 3(3, 4) µg/dl in controls, respectively 
(p<0.000).  BMI, income, marital status, blood pressure, smoking, alcohol intake were 
comparable in the two groups.  However, exposed workers were less educated than 
controls.  Bone lead levels were correlated to systolic blood pressure in exposed workers, 
spearman’s correlation =0.27, (p<0.009).  In exposed workers, there was an inverse 
correlation between diastolic blood pressure and total cognitive score: (r =0.23; p<0.03), 
motor function(r=0.25; p<0.02), spatial function(r=0.25; p<0.02), and general intelligence 
(r=0.21; p<0.05). 
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Group Analysis (Stratified by Exposure) 
At v2, unadjusted mean total cognitive score, spatial function and general intelligence 
scores were significantly lower in exposed than control workers (p<0.001; Table 5-2).  
After controlling for covariates, higher bone lead levels were associated with lower scores 
in exposed workers than controls for all 5 cognitive domains achieving significance for total 
score (p<0.05), spatial function (p<0.001), learning and memory function(p<0.10).(Table 5-
3).  In addition, in exposed workers higher blood lead levels were associated with 
decreased scores on learning and memory function (Model 3; p<0.10).  However, higher 
blood lead levels also predicted poorer performance for control workers in motor domain in 
addition to general intelligence and learning and memory(Model 3; p<0.10 for all; Table 5-
3).  
When both blood and bone lead were analyzed together in exposed workers 
(Model 4) higher bone lead was a significant predictor of decreased total cognitive score, 
spatial function, and general intelligence (p<0.05 for all). Blood lead levels and presence 
of bone lead level in Model 4, were inversely associated with general intelligence in control 
workers.  (p<0.10). 
Exposed: Within group analysis (Stratified by age: ≥55, <55 years) 
In age stratified analysis, for lead exposed workers age ≥55, higher bone lead levels 
predicted  lower test scores for total cognitive score (p<0.05), spatial(p<0.01) and learning 
and memory function(p<0.10; Table 5-5).  Blood lead levels in the age ≥ 55 models 
predicted negative association with learning and memory score (p<0.10) and positive 
association with general intelligence (p<0.10; 4).  When both bone and blood lead were 
analyzed together in this model,  in workers age ≥ 55, higher tibia lead levels predicted 
decreased total cognitive score (p<0.05), spatial function(p<0.01) and general intelligence 
function(p<0.05) and learning and memory (p<0.10).  In the same model blood lead levels 
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predicted a significant positive association with general intelligence (p<0.05). The 
interactions between biomarkers, age and cognitive domains were not significant.  
Change Score (v1 to v2) 
The change score models were compared for exposed and control workers only with bone 
lead.  After controlling for confounding variables, higher bone lead in exposed workers 
predicted cognitive decline over time for total cognitive score, executive function(p<0.05 
for both) and spatial function (p<0.01;Table 5-7). 
To interpret magnitude of decline in test scores, we describe the mean proportional 
difference that would be associated with an increase in lead biomarkers.  Specifically, the 
ß coefficients from models were multiplied with 50 for bone lead, 10 for blood lead, and 5, 
for age.  For total cognitive score in exposed workers, the decrement associated with an 
increase of 50 µg/g bone lead was comparable in magnitude to the cognitive decline 
associated with 5 years of age (Table 5-4., CoI.1).  In exposed workers, age 55 or older 
magnitude of cognitive change declined further, more than twice that of 5 years of age 
related change (Table 5-6, Col 1).  Comparison of proportionate cognitive change, from v1 
to v1, over 22 years was comparable to age associated cognitive decline by 5 years.  
(Table 5-8.  Col.1) 
5.5 DISCUSSION 
In this cohort of middle aged men with an average occupational lead exposure of 25 years 
and 22 years between initial and follow-up cognitive testing, the presence of higher bone 
lead levels was predictive of lower total cognitive scores at the follow up evaluation.  
Cognitive function in the spatial, and learning and memory domains was also significantly 
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decreased.  Regression coefficients were negative for psychomotor function, general 
intelligence and executive function.  The association with cognitive decrement was not 
explained by education, income, lifestyle, and employment variables.  Higher bone lead 
concentration was also associated with decline in performance over time from 1982 to 
2004 for total cognitive score, spatial function and executive function [26, 27]. The 
cognitive decline was more pronounced in older lead workers.  This association was seen 
even after controlling for other risk factors.  To our knowledge this is the first study to 
explore the association of bone lead levels with the longest follow up time (average 22 
years) for the same occupational cohort.  
Our results corroborate and extend those suggested by several cross-sectional 
studies that found an inverse association between measures of cumulative lead exposure 
and tests of cognitive function in occupational cohorts and general population[30-32]. One 
of the population studies reported significant association of blood lead levels as low as 8 
µg/dl with impairment on several neuropsychological tests among a cohort of rural women 
but not urban women [28].  
Several occupational studies have reported the relationship of cross sectional(e.g., 
blood lead levels) as well as cumulative exposure(e.g., bone lead) with cognitive 
decrement[19, 33-37].  Acute exposures to high levels of lead among adults has been 
associated with deficits in performance on visuospatial skills, motor function, reaction time,  
memory, spatial function,  and attention and concentration in lead exposed workers [34, 
38-44].  Fewer studies have examined the association between cumulative lead exposure 
[32].  More recent studies have examined this issue using K-XRF technology to measure 
lead in bone.  
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A recent longitudinal study by Schwartz and colleagues compared and contrasted 
associations of blood lead and tibia lead with declines in cognitive function over the course 
of 2.2 years in subjects with current and past occupational exposure to inorganic lead[33]. 
There were consistent associations of blood lead with test scores at baseline and of tibia 
lead with declines in test scores over the next year, mainly in executive abilities, manual 
dexterity, and peripheral vibration threshold.  The results support the inference that lead 
has an acute effect on neurobehavioral test scores as a function of recent dose and a 
longer-term (possibly progressive) effect on cognitive decline as a function of cumulative 
dose[33].  
Recent research suggests that cognitive decline due to lead is progressive, even 
after the exposure ceases.  A study of older former organolead workers(n=118; mean age 
of 56) who had not been exposed to lead for 16 years found that bone lead levels were 
associated with changes on cognitive tests over a 4 year span.  Compared to controls, 
former lead workers performed worse over time for three tests of visuo-constructive ability 
and verbal memory and learning (p < 0.05).  In the lead workers, bone lead also predicted 
declines for six tests of verbal memory and learning, visual memory, executive ability, and 
manual dexterity (p < 0.05 for four tests and < 0.10 for two additional tests)[18]. In general, 
the domains that have been consistently associated with bone lead concentration are 
executive function/attention and visuospatial/ visuomotor tasks, although associations with 
verbal and memory tasks has also been noted [19, 34, 36, 45, 46].  
The mechanism underlying the effects of lead on the central nervous system have 
been of more recent interest [12, 18, 33, 34, 43, 47]. Lead is reported to effect specific 
areas in the brain such as the hippocampus, cerebellum, and frontal cortex [48-62].  Lead 
alters the permeability of the blood brain barrier[63], and accumulates in astroglia, which 
are essential for maintenance of neuronal environment[64]. Lead exposure can interfere 
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with several calcium dependent processes[65].  Lead activates protein kinase C 
(PKC)which has been implicated in neurotoxicity [65]. Magnetic Resonance Imaging (MRI) 
studies have reported an association of higher tibia lead  with increased prevalence and 
severity of white matter lesions and smaller structure-specific brain volume [23]. Cerebral 
white matter changes  on MRI are associated with higher bone lead levels and 
psychomotor slowing as measured by Grooved Pegboard test [23, 36, 66]. Tibia lead has 
been  associated with the strongest effects on verbal memory and learning, visual 
memory, and executive function which  may indicate disruption of widely distributed neural 
networks involved in the integration of functions and would be consistent with lesions to 
cortical association areas[23].  
The studies by Stewart and colleagues suggest that adult exposure to lead may 
accelerate age-associated brain changes. Myelination continues into the fifth and possibly 
sixth decade of life in selective brain regions (e.g., inferior temporal, prefrontal, and 
temporoparietal regions).  White matter produced later in life around cells with long but 
small caliber projections in cortico-cortical association areas may be sensitive to oxidative 
stress[66]. The significant associations of tibia lead with the parietal white and gray matter, 
and temporal white matter, suggest that lead accelerates an age-associated process in 
selected brain regions.  No significant associations were observed in regions where 
myelination occurs early in life (e.g., occipital lobe and cerebellum) and where short axonal 
projections are relatively common[8]. 
Lead exposure is a risk factor for hypertension, which may cause cerebrovascular 
disease leading to poor performance on cognitive tests.  [67-69].  High blood pressure also 
correlated with number of white matter lesions and total brain volume[23, 70]. We defined 
blood pressure as systolic blood pressure divided by diastolic blood pressure.  A positive 
correlation was noted between systolic blood pressure and bone lead in lead exposed 
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male workers (spearman correlation:  0.28, p<0.009).  In exposed lead workers significant 
inverse correlation was observed between diastolic blood pressure and scores on several 
cognitive tests. 
Decreased ratio of N-acetylaspartate (NAA) to creatine, a marker of neuronal 
density in hippocampus and frontal lobe as measured by Magnetic Resonance 
Spectroscopy (MRS) neuroimaging studies, is associated with higher bone lead levels and 
deficits on attention executive function, visuospatial /visuomotor functioning and short term 
memory [71].  Lead induces neurofibrillary tangles in  frontal cortex and hippocampus [21, 
22, 24] and is selectively toxic to limbic system, that modulates behavior, emotions, 
learning and memory[24]. 
Lead and homocysteine are both associated with cardiovascular disease and cognitive 
dysfunction[72]. An association between blood lead and homocysteine has been 
documented which suggest that homocysteine could be a mechanism that underlies the 
effects of lead on the cardiovascular and central nervous systems, possibly offering new 
targets for intervention to prevent the long-term consequences of lead exposure[72, 73]. 
We tried to overcome some of the methodological weaknesses in earlier research 
which included sampling inadequacies, selection bias, and variation in data collection 
procedures, and reliance on current indices of lead exposure rather than cumulative 
exposure indices.  There are a number of strengths to our study.  We studied a well-
characterized cohort of lead exposed and control men, using state-of-the-art 
measurements of K-XRF and controlled for a number of important covariates.  However 
there may be a bias in this study. At v1 the authors had reported no significant differences 
between exposed and non-exposed workers except psychomotor speed [26, 27]. However 
when we compared the v1 unadjusted mean scores between exposed and non-exposed 
for the current cohort , there were significant differences between spatial and general 
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intelligence function in addition to psychomotor scores.  The workers that came back for 
v2 might be the ones who performed at the lowest range of cognition at initial evaluation.  
A national public health objective for 2010 is to reduce the blood lead levels ≥25 
µg/dL among employed adults to zero[74]. The current blood lead levels ≥ 40 µg/dL, the 
level at which the Occupational Safety and Health Administration (OSHA) requires workers 
to have an annual medical evaluation, may need to be lowered.  Projections using 1994-
2004 ABLES (CDC’s state-based Adult Blood Lead Epidemiology and Surveillance) data 
trends indicate that the national prevalence rate of adults with blood lead levels ≥25 µg/dL 
will be approximately 5.7 per 100,000 employed adults in 2010.  Increased prevention 
measures in work environments, will be necessary to reduce this rate to zero and 
decrease risk of cognitive decline in the workforce. 
The magnitude of cognitive change associated with normal aging may be affected 
by environmental neurotoxicants like lead, effects which are persistent and progressive.  
Lead absorbed during occupational exposure induces neuronal structural damage which is 
nonreversible and may accelerate the age related structural and functional changes in 
brain function later in life.  In summary, this analysis suggests that higher tibia lead 
concentrations predict a steeper decline over time in performance on the cognitive test in 
an occupational cohort of men; cognitive decrement was more pronounced in older 
workers.  While circulating lead in blood may predict performance on some cognitive tests, 
the change in cognition over time is associated with cumulative exposure to lead.  
Cognitive decline with aging is one of the common public health concerns.  It 
impairs the quality of life of affected individuals and their caregivers.  Impaired cognition 
among adults is associated with functional decline in activities of daily living, increased risk 
of injury to self and others, associated demands on caregivers, and an increased risk of 
mortality.  Although not as severe, even mild cognitive impairment is recognized as a 
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transitional state between normal aging and dementia.  The cognitive impairment 
associated with lead exposure may be preventable.  
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 Table 5-1 Socio-demographic characteristics  in exposed and control male lead workers in 2004. 
 
N=141 
 
Controls 
n=52 
 
Exposed 
n=89 
 
P -value 
Age (years) mean (sd) 55(9) 54(9) 0.458 
BMI (kg/m2) mean (sd) 31(6) 30.6(6) 0.739 
Education (years) mean (sd) 12.2(1.8) 11.34(1.7) 0.005 
Income (1000 $/yr) n (%) 
      > 40 
      ≤ 40 
 
28(54) 
24(46) 
 
51(57) 
38(43) 
 
0.690 
Marital Status, n (%) 
       Married 
       Not Married 
 
44(85) 
8(15) 
 
74(83) 
15(17) 
 
0.820 
Smoker, n (%) 10(19) 23(26) 0.371 
Drinks (per wk), median*(Iqr)‡ 2(0,3) 1(0,4) 0.342 
Systolic Blood Pressure (mm Hg) mean (sd) 130(18) 127(17) 0.191 
Diastolic Blood Pressures (mm Hg) mean (sd) 78.2(9) 77.9(9) 0.848 
Systolic Hypertension§ n (col %) 14(27) 17(19) 0.279 
Diastolic Hypertension  6(12) 9(10) 0.791 
Blood lead(µg/dl) median (Iqr) 3(3,4) 12(8,19) <0.000 
Bone lead (µg/g bone mineral) median(Iqr)  12(-8,32) 57(20,86) <0.000 
Employment (years) mean (sd) 27(7) 25(8) 0.188 
Since last worked  (years) mean (sd) 0.04(0.3) 0.33(0.3) 0.007 
*Non-parametric Wilcoxon, Mann Whitney U test 
§ Defined as systolic blood pressure>140 or diastolic blood pressure >90 mm of Hg 
‡Iqr=Inter quartile range  
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Table 5-2 Unadjusted Mean Cognitive scores in 1982 and 2004 in lead-exposed and control 
male workers. 
 
Cognitive  
Domain 
1982 
Mean score (sd) 
2004 
Mean score (sd) 
 Controls 
n=52 
Exposed 
n=89 
p-value Controls 
n=52 
Exposed 
n=89 
p-value 
       
Total score  0.00(2) -1.09(3) 0.012** -0.00(2) -1.35(3) 0.008*** 
       
Motor 0.00(3) -1.21(3) 0.031** -0.00(3) -1.27(5) 0.105 
       
Spatial 0.00(3) -1.53(4) 0.013** 0.00(3) -1.88(4) 0.003*** 
       
Executive 0.00(2) -0.26(3) 0.545 -0.00(2) -0.63(3) 0.139 
       
Gen. Intel. ‡ 0.00(2) -1.24(2) 0.003*** 0.00(3) -1.54(3) 0.000*** 
       
Memory 0.03(4) -1.25(6) 0.153 -0.00(5) -1.43(6) 0.119 
       
*significant p-value in bold letters, at *<0.10,   **<0.05, ***<.01 
‡ General Intelligence 
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Figure 5-1 Adjusted total Z-score and bone lead levels in exposed and control male workers in 2004 
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Figure 5-2 Adjusted total Z-scores and bone lead levels in control and exposed male workers by age 
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Table 5-3  Multiple Regression Models for Cognitive Domain Z-Scores in 2004 in Lead Study workers with Sequential Adjustment for Blood Lead and 
Bone Lead. 
 
 
 
Significant at *<0.10,   **<0.05,  ***<.01 
@Model 1= Age, education, income, marital status, years of employment, years since last worked , smoking , drinks/wk, and BP  
†Model 2= Model 1+ Bone lead  ,   
‡Model3=  Model 1+ Blood  Lead  ,  
 §Model 4= Model 1+Bone lead+ Blood lead . 
 
 
 
Cognitive Domain 
 
Total Score 
 
Motor 
 
Spatial 
 
Executive 
 
Gen. Intel 
 
Memory 
 
Model 1@ 
Exp 
N=83 
 
Con 
N=52
Exp Con 
 
Exp Con 
 
Exp Con 
 
Exp Con 
 
Exp Con 
 
Model 2† 
Bone Lead 
-0.01** 0.00 -0.00 -0.00 -0.02*** -0.00 -0.00 0.00 -0.01 0.00 -0.02* 0.00 
Model 3‡ 
Blood Lead 
-0.05 -0.53 -0.06 -1.15* -0.05 0.41 -0.05 -0.47 0.06* -0.48* -0.13* -0.92*
 
Bone Lead 
 
-0.01**
 
0.00 
 
 
-0.00
 
 
-0.00 
 
 
-0.02** 
 
 
-0.00
 
-0.01 
 
 
-0.00
 
-0.01**
 
-0.00 
 
-0.02 
 
0.00 
Model 4§ 
Blood Lead  
 
-0.03 -0.53 -0.06 -1.15* -0.03 0.41 -0.04 -0.02 0.07** -0.48* -0.11 -0.92*
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Table 5-4 Cross-Sectional Analysis: Cognitive test scores and (95% CI) in Lead exposed workers in 2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Significant at *<0.10,   **<0.05,  ***<.01 
@Model 1= Age, education, income, marital status, years of employment, years since last worked , smoking , drinks/wk, BP   
†Model 2= Model 1+ Bone lead  , 
 ‡Model3=  Model 1+ Blood  Lead  ,    
§Model 4= Model 1+Bone lead+ Blood lead . 
 
 
 
 
Estimate  
(95% C I) 
(N, Exposed=83) 
 
Total Score
 
Motor 
 
Spatial 
 
Executive 
 
Gen. Intel 
 
Memory 
Age  
Effect estimate per 5 yrs 
-0.55*** 
(-0.91,-.19) 
-1.22*** 
(-1.79,-.66) 
-0.58*** 
(-1.00,-1.15) 
0.03 
(-0.40,0.46)
0.37 
(-0.00,0.75) 
-1.42*** 
(-2.12,-0.71)
Bone Lead,  
Effect estimate per 50 µg/g 
-0.58** 
(-1.05,-0.11)
-0.13 
(-0.84,0.58) 
-0.88*** 
(-1.51,-0.25) 
-0.46 
(-1.02,0.09)
-0.39 
(-0.88,0.09) 
-1.03* 
(-2.15,0.08) 
 
Blood Lead,  
Effect estimate per 10 µg/dl
-0.47 
(-1.10,0.16) 
-0.64 
 (-1.51,0.23)
-0.48 
(-1.46,0.49) 
-0.49 
(-1.16,0.19)
0.59 
(-0.01,1.20) 
-1.34 
(-2.90,0.22) 
 
Bone Lead,  
Effect estimate per 50 µg/g 
 
Blood Lead,  
Effect estimate per 10 µg/dl
-0.54** 
(-1.00,-0.07)
 
-0.34 
(-0.94,0.27) 
-0.05 
(-0.78,0.67) 
 
-0.63 
(-1.53,0.27) 
-0.85*** 
(-1.49,-0.21) 
 
-0.27 
(-1.25,0.71) 
-0.42 
(-0.97,0.14)
 
-0.38 
(-1.05,0.29)
-0.48** 
 (-0.95,-0.02)
 
0.71** 
 (0.09,1.33) 
-0.90 
 (-1.99,0.21) 
 
-1.11 
 (-2.63,0.40) 
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Table 5-5 Multiple Regression Models for Cognitive Domain Z-Scores in 2004 in Exposed Lead Study workers stratified by age 
 
 
 
Significant at *<0.10,   **<0.05,  ***<.01 
@Model 1= Age, education, income, marital status, years of employment, years since last worked , smoking , drinks/wk, BP 
†Model 2= Model 1+ Bone lead  ,  
 ‡Model3=  Model 1+ Blood  Lead  ,   
 §Model 4= Model 1+Bone lead+ Blood lead . 
 
 
Cognitive Domain 
 
Total Score 
 
Motor 
 
Spatial 
 
Executive 
 
Gen. Intel 
 
Memory 
 
 
 
Model 1@ 
≥ 55 yr 
N=29 
<55 yr
N=54 
≥ 55 yr <55 yr ≥ 55 yr <55 yr ≥ 55 yr <55 yr ≥ 55 yr <55 yr ≥ 55 yr <55 yr
 
             
Model 2† 
Bone Lead 
 
-0.02** 0.00 -0.01 -0.00 -0.03*** -0.00 -0.02 -0.00 -0.01 -0.00 -0.03* 
 
-0.01 
 
Model 3‡ 
Blood Lead 
 
-0.08 -0.02 -0.07 -0.05 -0.06 0.01 -0.06 -0.02 0.13* -0.05 -0.28* -0.04 
Bone 
 
-0.02** 
 
-0.00 
 
-0.00 
 
-0.00 
 
-0.03***
 
-0.01 
 
-0.02 
 
0.00 
 
-0.01**
 
-0.00 
 
-0.02* 
 
-0.01 
 
 
Model 4§ 
Blood 0.03 -0.01 0.02 -0.05 -0.00 0.01 -0.03 -0.03 0.14** 0.04 -0.21* -0.04 
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Table 5-6 .  Cross-Sectional Analysis: Cognitive test scores and (95% CI) in Lead exposed workers in 2004 stratified by age (<55, ≥55 yrs) (Expressed 
per 50 µg/g increase of bone lead, per 10µg/dl increase of blood lead and per 5 increases of years in age). 
 
 
 
Significant at *<0.10,   **<0.05,  ***<.01 
@Model 1= Age, education, income, marital status, years of employment, years since last worked , smoking , drinks/wk and BP  
†Model 2= Model 1+ Bone Lead  ,  
 ‡Model3=  Model 1+ Blood Lead  ,   
 §Model 4= Model 1+Bone lead+ Blood lead . 
 
Cognitive Domain 
 
Total Score 
 
Motor 
 
Spatial 
 
Executive 
 
Gen. Intel 
 
Memory 
 
Age in years 
 
≥ 55 
N=29 
<55 
N=54 
≥ 55 <55 ≥ 55 <55 ≥ 55 <55 ≥ 55 <55 ≥ 55 <55 
 
             
Model 2† 
Bone Lead Effect 
estimate per 50 µg/g 
 
-0.88** -0.22 -0.17 -0.11 -1.66*** -0.35 -0.65 -0.06 -0.50 -0.15 -1.48* 
 
-0.48 
 
Age Effect estimate 
per 5 yrs 
-0.39 -0.20 -1.14 -0.81 0.06 -0.17 -0.65 0.26 0.48 0.24 -1.12 -0.48 
             
Model 3‡ 
Blood Lead Effect 
estimate per 10 µg/dl 
 
-0.79 -0.16 -0.69 -0.51 -0.83 -0.19 -1.00 -0.19 1.47* 0.57 -2.79* -0.44 
 
 
Bone 
 
-0.84** 
 
-0.20 
 
-0.09 
 
-0.03 
 
-1.67*** 
 
-0.33 
 
-0.56 
 
-0.03
 
-0.75** 
 
-0.24 
 
-1.20*
 
-0.43 
 
 
Model 4§ 
Blood -0.33 -0.13 -0.65 -0.51 0.05 -0.13 -0.71 -0.18 1.87** 0.61 -2.14* -0.36 
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Table 5-7 Multiple Regression Models for Cognitive Domain Z-Scores Change from 1982 to 2004 in Lead Exposed Workers with Sequential 
Adjustment for Bone Lead. 
 
 
 
Significant at *<0.10,   **<0.05, ***<.01 
@Model 1= Age, education, income, marital status, years of employment, years since last worked, smoking, drinks/wk, BP 
†Model 2= Model 1+ Bone Lead   
 
 
 
 
 
 
Cognitive 
Domain 
 
Total Score 
 
Motor 
 
Spatial 
 
Executive 
 
Gen. Intel 
 
Memory 
 
 
Model 1@ 
 
 
 
 
 
 
 
 
 
 
 
 
 
Model 2† 
Bone Lead 
-0.0074** -0.0034 -0.0140*** -0.0096** -0.0055 -0.0033 
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gnificant at *<0.10,   **<0.05,  ***<.01 
Model 1= Age ,education, income, marital status, years of employment, years since last worked , smoking , drinks/wk and BP  
odel 2=  Model 1+ Bone Lead   
 
Cognitive Domain 
 
Total Score 
 
Motor 
 
Spatial 
 
Executive 
 
Gen. Intel 
 
Memory 
 
 
Model 1@ 
Exp Con 
 
Exp Con 
 
Exp Con 
 
Exp Con 
 
Exp Con 
 
Exp Con 
 
             
Model 2† 
Bone Lead Effect  
estimate per 50 µg/g 
-0.37** 0.18 -0.17 -0.07 -0.72*** -0.03 -0.48** 0.42 -0.28 -0.03 -0.16 0.61 
             
Age Effect estimate  
per 5 yrs 
-0.41*** -0.47** -1.12*** -0.92** -0.26 -0.24 0.01 -0.41 0.17 0.27 -0.82*** -0.73
             
. 
Table 5-8 Cognitive test change scores and (95% CI) in Lead exposed and control workers from 1982 to 2004 ( expressed per 50 µg/g increase of bone 
lead, per 10µg/dl increase of blood lead and per 5 increase of years in age). 
  
6.0  DISCUSSION 
6.1 SUMMARY OF FINDINGS 
This prospective analysis examined the association of lead biomarkers with changes in 
bone mineral density (BMD), incident fractures and falls, cognition and mortality.  In the 
SOF analysis, baseline total hip BMD was lower in women with high blood lead levels.  
The annualized rate of decline in hip BMD was greater among women with high blood lead 
level, who also experienced a two-fold increased risk of fracture and falls.  Women with 
higher blood lead levels at baseline had increased risk of all cause, and cardiovascular 
mortality compared to women with lower blood lead levels.  These relationships were 
independent of age and shared risk factors between blood lead levels and BMD, fractures, 
falls and mortality.  
Our study findings in elderly women are an important addition to existing literature 
as this is the first longitudinal study to report an inverse relationship between lead levels 
and BMD decline in total hip and femoral neck.  These associations are consistent with a 
recent report of vertebral BMD decline in women  52 years of age (range, 39–68 years) 
who had occupational  lead exposure[48, 49, 204].  In a longitudinal analysis across 6 
years, after controlling for baseline spine BMD, baseline blood lead, time since 
menopause, and occupational exposure, every log unit increase in blood lead measured at 
follow-up resulted in a decrease of -0.039 (g/cm 2) in spine BMD.  In NHANES II ( 1976-
1980) in both black and white women there was a highly significant increase in blood and 
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calculated plasma lead concentration after menopause[52]. In another study both cortical 
and trabecular bone lead measures were significantly and positively associated with blood 
lead in among postmenopausal women not using estrogen[47]. The observed interaction 
of bone lead with estrogen status in determining blood lead supports the hypothesis that 
increased bone resorption, after menopause because of decreased estrogen production, 
results in heightened release of bone lead stores into blood.  Women in our study with 
higher blood lead level had lowest intake of estrogen and Vitamin D.  
In women we observed a two fold increased risk of non-spinal, non traumatic 
fractures that had higher blood lead levels.  Notably this association was observed after 
controlling for age as well as other fractures risk factors.  To our knowledge, no other 
study has explained the association of blood lead levels and fracture risk in older human 
subjects.  In children stunted stature is reported after lead exposure.  In one study of 7-15 
years old children blood lead level was inversely related to reduced height, trunk, leg, and 
arm lengths. The estimated reduction in height was 5cm/ 10 ug /dl increase in blood lead 
levels.  The reduction in height occurred primarily in leg length and  was more marked in 
the female children  [80, 205].  The inverse relationship of blood lead levels to stature was 
also evaluated in children aged 5-12 years, derived from the data sets of the Hispanic 
Health and Nutrition Examination Survey (HHANES) conducted in 1982-1984.  There was 
an inverse relationship between blood lead with stature  [93].  Animal models explain 
higher incidence of fractures with higher blood lead levels[87, 88].  
There is paucity of literature on the association between lead exposure and risk of 
falls.  We observed two fold higher risks of incident falls in women with higher blood lead 
levels even after controlling for age and risk factors.  Reports of occupational lead 
exposure and impaired postural balance and vibration sensitivity are documented[113]. 
  114
Children who survive acute lead encephalopathy suffer from ataxia and have difficulties 
maintaining postural equilibrium[206].  
Growing children who had higher exposures to lead during first two years of life 
(CNS development) were observed to have  more postural sway, and the body balance 
was affected ,suggestive of, lead causing  impairment in the functional capacities or 
interconnectivity of the vestibular systems and/or proprioception (position of joints) at 2 
years of age [112, 116, 206-208]. Maintaining balance and proprioception are cues to 
physiological posture, and if disturbed may predispose to falls.  
In mortality analysis, we found that elderly women with higher blood lead levels at 
baseline had increased risk of all cause, and cardiovascular mortality compared to women 
with lower blood lead levels.  The cardiovascular risk factors such as hypertension, history 
of angina, stroke did not explain this association.  An association between blood lead 
levels and mortality has been reported from analysis of data in NHANES surveys.  In one 
study that reported inverse  association of blood lead levels below 10 µg/dl  with all-cause 
and cause-specific mortality from analysis of NHANES III (1988 to 1994), with participants 
followed up for up to 12 years.  When cause-specific deaths were investigated, the 
increased mortality was concentrated in cardiovascular deaths, which is similar to our 
results. Women in SOF sub study had three to four fold higher CVD mortality risk at higher 
blood lead level[148]. We had much lower sample size as compared to this study 
(N=13,946) and therefore some of the  
No association with cancer mortality was found in this range of blood lead.  The 
finding of no increased cancer mortality risk in our study, and NHANES III study are 
consistent with experimental evidence in which increased numbers of tumors are induced 
in rodents only after relatively high doses.  Accumulating evidence indicates that blood 
lead levels <10 µg/dl are associated with peripheral arterial disease, impaired renal 
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function, and elevated blood pressure[135-138, 209].  The present study adds important 
data on total and cardiovascular mortality, end points of unquestionable public health 
relevance. 
In Lead Occupational study, compared to controls, lead exposed workers had 
lower total cognitive scores.  Their performance was also decreased on spatial, memory 
and general intelligence domains cross-sectionally.  In longitudinal analysis, cognitive 
scores of lead exposed workers declined more in total, spatial and executive domains, as 
compared to controls. Age and important risk factors between lead exposure and cognitive 
change did not explain this association.  To our knowledge this is one of the longest follow 
up for cognitive function assessment in a cohort of lead exposed male workers.  One of 
the strengths of this study was the availability of control group for comparison.  The results 
are concurrent with  studies that have reported association of tibia lead exposure with 
cognitive decline[153, 181, 184, 185, 190, 210, 211].  
The findings from the SOF lead sub study need to be considered within the context 
of its limitations.  An important limitation was the reliance on a single blood lead 
measurement to assess exposure.  Blood lead, with a half-life of 30 days, reflects primarily 
recent external exposures, although it is also influenced by long-term exposures through 
endogenous recirculation of lead from skeleton.   Thus, it is unclear whether the adverse 
health effects of lead observed here were associated with current or cumulative 
exposures.  The findings of this study may not be generalizable, as men and women of 
other races were not included.  
Despite these limitations, the study has several strengths.  SOF data were 
collected by a rigorous study protocol with extensive quality control procedures and 
accurate follow up.  To the best of our knowledge, the SOF BMD, fracture, and mortality 
study is the only prospective study besides the data analyses reported from NHANES.  
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One of the limitations of the lead occupational study is a bias.  At the initial 
cognitive evaluation in 1982, 288 exposed and 181 control male lead workers were 
reported to perform equally well on measures of learning, memory, attention, visuospatial 
ability, and general intelligence.  The exposed workers were reported to differ from 
controls only on one measure of psychomotor speed and manual dexterity, the Grooved 
Pegboard Test, and these between-group differences were restricted to the older lead 
workers [212, 213].  The records have been de-identified, except the cognitive scores from 
1982.  When we compared the 2004(v2) unadjusted scores to the 1982(v1) we found 
significant differences at both v1 and v2 for the current participants.  There is the 
possibility that only the exposed workers who had decreased score at v1 came back for 
v2.  Moreover, we did not have XRF assessment for v1. 
In spite of these limitations, we were able to observe significant differences in 
several cognitive functions due to prolonged lead exposure.  The range of blood lead 
levels (8-19µg/dl) reported at v2 is almost half of that reported from v1.  The association 
detected at the present lower level provides new evidence of the adverse impact of lead at 
levels that is still considered by acceptable, particularly for occupational settings.  
6.2 PUBLIC HEALTH SIGNIFICANCE 
Current population blood lead levels are estimated to be substantially higher than blood 
lead levels in preindustrial period.  Although a 10-fold decline in blood lead levels has 
occurred in the United States in recent decades, current levels remain higher for 
occupationally exposed, children and elderly.  In one report of lead effects on mortality 
from NHANES, the association of blood lead with cardiovascular mortality was evident at 
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levels as low as 2 µg/dl.  Because 38% of US adults had lead levels >2 µg/dl in NHANES 
1999 to 2002, the public health implications of these findings are substantial. The health 
effects of current lead levels on adult populations, however, are not viewed as a pressing 
public health concern.  The present study, in conjunction with previous data, indicates that 
this perception may be erroneous and that acceptable blood lead levels in adults need to 
be lowered further. 
Overall, our findings provide epidemiological evidence for the presence of an 
association between lead exposure, morbidity and mortality in community residing elderly 
women as well as a male occupational cohort. A more stringent control of lead exposure 
and better understanding of the mechanism of its effects may help reduce the public 
health burden of disease. 
6.3 FUTURE RESEARCH 
The findings in our study for association of lead and multiple health effects could be 
validated in future studies, where bone lead levels in addition to blood lead levels would 
demonstrate cumulative environmental exposure assimilated in bones.  Such a study 
would give a comprehensive picture of association of lead in the spectrum of changes 
seen in women’s early growth, reproductive years, and menopausal transition.  Women 
and men are respond differently to lead exposure across age periods, race and exposure 
levels.  It would be of high scientific interest if future studies could look in the temporal 
association of lead exposure across these strata.  
We have identified a possible association between bone mineral density, falls and 
fractures in addition to mortality and cognitive decline with lead.  Future endeavors could 
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elucidate the common pathway between cardiovascular morbidity and cognitive decline, 
both though to be associated with homocysteine levels.  The study of osteoporotic 
fractures has an invaluable array of data for anthropometric, biochemical measures across 
more than 20 years of follow-up, which could be used in future research to assess the 
common link between skeletal, cardiovascular and cognitive changes and lead. 
The lead male cohort is the longest occupational follow up to date.  Most of the 
participants are healthy.  The state of the art neuroimaging technology being used in 
University of Pittsburgh’s groundbreaking research could provide insight into the 
neurological effects of lead in this cohort. 
6.4 CONCLUSION 
Cardiovascular disease (CVD), cognitive decline, and osteoporotic fractures are major 
causes of morbidity, mortality, and disability which are commonly associated with normal 
aging.  Recent research has indicated a link between these age related outcomes to 
environmental and occupational lead levels.  Common biochemical processes such as 
calcium messenger system, has been implicated in skeletal, cardiovascular and 
neurological pathways.  Homocysteine levels are associated with cardiovascular and 
neurological disturbance.  Vitamin D has been associated with fractures, falls, and bone 
mineral density changes.  All of these processes are disturbed by lead exposure.  Future 
research could investigate the common underlying mechanism, these findings may help 
tailor targeted preventive and therapeutic approaches. 
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